A compound as a protein kinase inhibitor and its preparation method and use
By developing compounds with specific structures, the problems of drug resistance and side effects of existing ALK inhibitors have been solved, and effective inhibition of ALK, ROS1 and TRK kinases have been achieved, with broad clinical application prospects.
Patent Information
- Application Number
- CN202111080921.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-06-21
- Filing Date
- 2020-06-10
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-06-10
AI Technical Summary
Existing ALK inhibitors are prone to drug resistance when treating non-small cell lung cancer, and have great side effects, which limits their clinical application.
A novel compound has been developed with structural features including specific cycloalkyl and heterocycloalkyl structures with broad spectrum of ALK, ROS1 and TRK inhibitory activities that inhibit their activity by binding to specific sites of protein kinases.
This compound significantly inhibits the activity of ALK, ROS1 and TRK kinases, has better pharmacokinetic properties than the clinical phase II TPX-0005, and has a potential to be widely used in the treatment of malignant tumor diseases and inflammatory diseases.
Smart Images

Figure QLYQS_1 
Figure QLYQS_2 
Figure QLYQS_4
Abstract
Description
[0001] This invention is a divisional application of Chinese patent application CN202010525613.2, and the application date of the parent application is 2020.06.10. Technical Field
[0002] The present invention relates to the field of medical technology, and in particular to a compound used as a protein kinase inhibitor, and a preparation method and use thereof. Background Art
[0003] Lung cancer is one of the malignant tumors with the fastest growing incidence and mortality rate and the greatest threat to human health and life. Among them, non-small cell lung cancer accounts for about 80% of all lung cancers, so the research on non-small cell lung cancer has been a hot topic in the past and at present. The main method for treating lung cancer is still molecular targeted therapy, mainly including ALK, EGFR, C-Met, ROS1, TRK and other targets. ALK (anaplastic lymphoma kinase) is a receptor tyrosine kinase that is involved in a variety of human cancers and human development. It is a member of the insulin receptor family and has a high homology with leukocyte tyrosine kinase. It is associated with three types of tumors: blood, interstitial and solid. In about 3-7% of patients with non-small cell lung cancer (NSCLC), the exon of the tumor chromosome EML4 gene fuses with the exon of the ALK gene to form the EML4-ALK fusion tyrosine kinase. The EML4-ALK fusion variant is highly carcinogenic, and ALK is highly expressed in a variety of tumor cells. ROS1, the full name of c-ros proto-oncogene, is a transmembrane receptor tyrosine kinase gene. Patients with ROS1 mutations are more likely to be young, non-smoking lung cancer patients, most of whom have lung adenocarcinoma. Mutants account for about 3% of the total number of NSCLCs. TRK (Tropomyosin-related kinase) is a tyrosine kinase of neurotrophic receptors present in a variety of tissues, activating a variety of downstream processes during cell proliferation and survival. The TRK proto-oncogene family has three members: TRKA, B and C, which are encoded by NTRK1, NTRK2 and NTRK3, respectively. Since the launch of larotrectinib, the world's first targeted drug for all types of cancer, in 2018, another "diamond" target gene, NTRK, has quickly become popular in the cancer circle. However, in common lung cancer, breast cancer, and colorectal cancer in China, only 1% to 5% of patients have this mutation. Although the incidence of NTRK fusion in NSCLC is very low, once the fusion mutation is found, the targeted drug has a high efficacy and can be actively treated with TKI, which has great potential and broad market prospects.
[0004] Breakthrough progress has been made in using ALK as a new target for the treatment of lung cancer, and it has developed into the fourth generation of macrocyclic inhibitors. Crizotinib, the first generation ALK inhibitor developed by Pfizer, came into being based on the discovery of the EML4-ALK target. Crizotinib is an ATP-competitive multi-target protein kinase inhibitor that can effectively inhibit the cellular biological activity of MET / ALK / ROS, and shows high clinical efficacy in tumor patients with abnormal ALK, ROS1 or MET kinase activity. Crizotinib is one of the fastest-developed drugs in the history of oncology drug development, and it caused a sensation after it was launched in the United States in 2011. In 2016, the U.S. Food and Drug Administration (FDA) approved crizotinib for the treatment of patients with advanced (metastatic) non-small cell lung cancer (NSCLC) carrying ROS-1 gene mutations.
[0005] However, with the launch of the first ALK drug, crizotinib, patients developed drug resistance within two years of continuous use. These drug resistances mainly include three types: one is the change of ALK gene, such as the "gatekeeper gene" mutation L1196M and the common mutation C1156Y, the insertion mutation 1151Tins, etc.; the second is the continuous amplification of ALK fusion gene; the third is the activation of bypass signals of ALK signaling pathway. In order to solve the drug resistance problem caused by crizotinib, in 2014, the FDA announced that Roche's alectinib (CH5424802) and Novartis's ceritinib (LDK378) are second-generation ALK inhibitor drugs for the treatment of lung cancer. In addition, in 2017, the FDA also launched another second-generation ALK inhibitor for the treatment of lung cancer, Brigatinib (Brigatinib), which is also the only drug with dual targets of EGFR and ALK. Although patients with acquired drug resistance have benefited a lot from these marketed drugs, the effectiveness of these therapies is often limited by some side effects or the problem of tumors acquiring drug resistance again. Therefore, there is an urgent need to develop new, highly effective and broad-spectrum kinase inhibitors.
[0006] On November 2, 2018, pharmaceutical giant Pfizer announced that the FDA approved the third-generation ALK kinase inhibitor lorlatinib developed by the company for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) patients. These patients developed resistance after receiving crizotinib or at least one other ALK inhibitor, or developed resistance after receiving alectinib or ceritinib as the first ALK inhibitor therapy. Although lorlatinib has a good blocking effect on most secondary resistance mutations, including the refractory ALK G1202R mutation, its clinical application is severely limited due to side effects such as hypercholesterolemia, hypertriglyceridemia, edema, and peripheral neuropathy.
[0007] At present, the fourth-generation ALK inhibitor TPX-0005 (lopretinib) developed by TP Therapeutics has entered the Phase II clinical study. It is a broad-spectrum ALK, ROS1 and TRK inhibitor that effectively targets a variety of acquired mutations, including ALK G1202R, ROS1 G2032R and TRKA G595R mutations. It has high inhibitor activity against crizotinib-induced resistance mutations, and also has a good inhibitory effect on resistance mutations generated by the use of second-generation ALK inhibitors, with fewer side effects. On June 28, 2017, TP Therapeutics announced that the FDA has issued orphan drug status to its clinical new drug compound TPX-0005 for the treatment of NSCLC patients with ALK, ROS1 or NTRK oncogene rearrangements.
[0008] TPX-0005 (lopretinib) has the potential to comprehensively address drug tolerance problems caused by drug-resistant mutations after targeting ALK, ROS1, and NTRK, but its efficacy and pharmacokinetic properties still have much room for improvement. Summary of the invention
[0009] The main technical problem solved by the present invention is to provide a compound capable of inhibiting protein kinase. To solve the above technical problem, a technical solution adopted by the present invention is:
[0010] Provided is a compound characterized by having a structure represented by formula (I) or its tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, a pharmaceutically acceptable hydrate, solvate or salt:
[0011]
[0012] in:
[0013] M1 is selected from CR 15 or N, M2 selected from CR 16 or N;
[0014] Ring E is selected from substituted or unsubstituted C3~C 15 A monocyclic, bicyclic or tricyclic cycloalkyl or heterocycloalkyl, wherein the heterocycloalkyl contains one or more O, NR 24 , S, S(O), S(O)2, wherein the substituents are independently selected from halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, hydroxy, cyano, amino, ester, amide, aryl, heteroaryl, and sulfonyl;
[0015] A1, A2, A3, A4, A5, A6 are independently selected from C, CR 17 , NH, N, and at least one of A1, A2, A3, A4, A5, A6 is N or NH;
[0016] Y is selected from CR 26 R 27 , O, NR 18 , S, S(O), S(O)2, C=O, C=S;
[0017] n is selected from 0 to 5;
[0018] R1, R2, R3, R9, R 15 , R 16 , R 17 , R 18 , R 26 , R 27 Each of the substituents is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted heteroalkyl or heterocycloalkyl, hydroxy, cyano, amino, ester, amide, aryl, heteroaryl, and sulfonyl;
[0019] R4 is selected from hydrogen, halogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted heteroalkyl or heterocycloalkyl, hydroxyl, cyano, amino, ester, amide, aryl, heteroaryl, sulfonyl, boric acid, phosphoryl, wherein the substituents are independently selected from halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, hydroxyl, cyano, amino, ester, amide, aryl, heteroaryl, sulfonyl;
[0020] R5, R6, R7, R8, R 22 , R 23R5, R6 and the carbon atoms to which they are attached constitute substituted or unsubstituted C3-10 cycloalkyl or heterocycloalkyl, or R7, R8 and the carbon atoms to which they are attached constitute substituted or unsubstituted C3-10 cycloalkyl or heterocycloalkyl, or R 22 , R 23 The carbon atoms to which they are connected constitute a substituted or unsubstituted C3-10 cycloalkyl or heterocycloalkyl, or the carbon atoms to which R5 and R8 are respectively connected and the saturated chain segment of the macrocyclic molecule between the two carbon atoms together constitute a substituted or unsubstituted monocyclic, bicyclic or tricyclic C3-10 cycloalkyl or heterocycloalkyl, or the carbon atoms and nitrogen atoms to which R5 and R9 are respectively connected together constitute a substituted or unsubstituted C3-10 heterocycloalkyl, or R 23 , R9 and the carbon atom, nitrogen atom and saturated chain segments of macrocyclic molecules between carbon atoms and nitrogen atoms to which they are respectively connected together constitute a substituted or unsubstituted C3-10 heterocycloalkyl;
[0021] Wherein, the heterocycloalkyl contains one or more O, NR 25 , S, S(O), S(O)2, wherein the substituents are independently selected from halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, hydroxy, cyano, amino, ester, amide, aryl, heteroaryl, and sulfonyl;
[0022] R 24 , R 25 is selected from hydrogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted heteroalkyl or heterocycloalkyl, hydroxyl, amide, aryl, heteroaryl, and sulfonyl, wherein the substituents are independently selected from halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, hydroxyl, cyano, amino, ester, amide, aryl, heteroaryl, and sulfonyl.
[0023] Further, ring E is selected from substituted or unsubstituted C3 to C 15 The monocyclic cycloalkyl group or the monocyclic heterocycloalkyl group is selected from the group consisting of:
[0024] In a further embodiment, ring E is selected from substituted or unsubstituted C3-C6 monocyclic cycloalkyl or monocyclic heterocycloalkyl.
[0025] Furthermore, the heterocycloalkyl group is an N-heterocycloalkyl group.
[0026] Further, the N heterocycloalkyl group is Among them, R 24 is selected from hydrogen, and substituted or unsubstituted alkyl.
[0027] Furthermore, the R 24 is selected from hydrogen, unsubstituted alkyl; further, said R24 Selected from hydrogen and methyl.
[0028] Further, it has a structure represented by formula (II) or its isomers, tautomers, mesomers, racemates, enantiomers, diastereomers or mixtures thereof, pharmaceutically acceptable hydrates, solvates or salts:
[0029]
[0030] Among them, R 10 , R 11 , R 12 , R 13 They are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, substituted or unsubstituted C1-6 alkyl or heteroalkyl, substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, wherein the substituents are independently selected from halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, hydroxyl, cyano, amino, ester, amide, aryl, heteroaryl, and sulfonyl.
[0031] Further, A4 is selected from N, A2 and A5 are independently selected from CR 17 , A1, A3, and A6 are independently selected from C and N, and A3 and A6 are different.
[0032] Furthermore, M1 is selected from CR 15 , M2 is selected from CR 16 or N.
[0033] Furthermore, R 16 Selected from H, halogen, C1-3 alkyl or heteroalkyl.
[0034] Furthermore, R 16 Selected from H, F, chloro, trifluoromethyl, difluoromethyl, methyl, methoxy.
[0035] Further, it has a structure represented by formula (III) or its tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, a pharmaceutically acceptable hydrate, solvate or salt:
[0036]
[0037] Among them, Y is selected from CR 26 R 27 , O, NR 18 ,S,S(O),S(O)2,C=O;
[0038] n is selected from 0, 1 or 2;
[0039] R2, R3, R4, R9, R 10 , R11 , R 12 , R 13 , R 14 , R 18 , R 26 , R 27 Each of the substituents is independently selected from hydrogen, halogen, hydroxyl, cyano, amino, substituted or unsubstituted C1-6 alkyl or heteroalkyl, substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, wherein the substituents are independently selected from halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, hydroxyl, cyano, amino, ester, amide, aryl, heteroaryl, and sulfonyl;
[0040] R5, R6, R7, R8, R 22 , R 23 R5, R6 and the carbon atoms to which they are connected constitute a substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, or R7, R8 and the carbon atoms to which they are connected constitute a substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, or R 22 , R 23 The carbon atoms to which they are connected constitute a substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, or the carbon atoms to which R5 and R8 are connected respectively and the saturated chain segment of the macrocyclic molecule between the two carbon atoms together constitute a substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, or the carbon atoms and nitrogen atoms to which R5 and R9 are connected respectively together constitute a substituted or unsubstituted C3-6 heterocycloalkyl, or R 23 , R9 and the carbon atoms, nitrogen atoms and saturated segments of macrocyclic molecules between carbon atoms and nitrogen atoms respectively form a substituted or unsubstituted C3-6 heterocycloalkyl, wherein the heterocycloalkyl contains one or more O or NR 25 , the substituents are independently selected from halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, hydroxy, cyano, amino, ester, amide, aryl, heteroaryl, and sulfonyl;
[0041] R 25 Selected from hydrogen, substituted or unsubstituted C1-6 alkyl or heteroalkyl, substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl; the substituents are each independently selected from halogen, hydroxyl, cyano, amino, ester, and amide.
[0042] 10. The compound according to any one of claims 1 to 9, characterized in that: Y is selected from CR 26 R 27 , O, NR 18 ; Further, Y is selected from CH2, O, NH.
[0043] Furthermore, n is selected from 0 and 1.
[0044] Furthermore, R5, R6, R7, R8, R 22 , R 23 R5, R6 and the carbon atoms to which they are connected constitute substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, or R7, R8 and the carbon atoms to which they are connected constitute substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, or R 22 , R 23 The carbon atom connected thereto constitutes a substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl group.
[0045] Furthermore, R5, R6, R7, R8, R 22 , R 23 R5, R6 and the carbon atom to which they are connected are independently selected from hydrogen, halogen, substituted or unsubstituted C1-6 alkyl or heteroalkyl, or substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl.
[0046] In a specific embodiment of the present invention, R5, R6, R7, R8, R9, R 22 , R 23 There is at least one loop between any two of them.
[0047] Here, at least one ring-forming situation between two of them means that among R5, R6, R7, R8, R9, R 22 , R 23 In the embodiment, at least one of the ring-forming conditions described in claim 1 exists, namely: ① R5, R6 and the carbon atoms to which they are connected constitute a substituted or unsubstituted C3-10 cycloalkyl or heterocycloalkyl; ② R7, R8 and the carbon atoms to which they are connected constitute a substituted or unsubstituted C3-10 cycloalkyl or heterocycloalkyl; ③ R 22 , R 23 The carbon atoms connected to them form a substituted or unsubstituted C3-10 cycloalkyl or heterocycloalkyl; ④ R5, R8, the carbon atoms connected to them respectively, and the saturated chain segment of the macrocyclic molecule between the two carbon atoms together form a substituted or unsubstituted monocyclic, bicyclic or tricyclic C3-10 cycloalkyl or heterocycloalkyl; ⑤ R5, R9, the carbon atoms and nitrogen atoms connected to them respectively, together form a substituted or unsubstituted C3-10 heterocycloalkyl; ⑥ R 23 , R9 and the carbon atom, nitrogen atom and saturated chain segments of macrocyclic molecules between carbon atoms and nitrogen atoms to which they are respectively connected together constitute a substituted or unsubstituted C3-10 heterocycloalkyl group; at least one of the six ring-forming situations exists.
[0048] Furthermore, R5, R6, R7, R8, R9, R 22, R 23 There is only one possible loop between any two pairs.
[0049] Furthermore, R5, R6, R7, R9, R8, R 22 , R 23 In the above, the non-cyclic group is selected from hydrogen, halogen, substituted or unsubstituted C1-6 alkyl or heteroalkyl.
[0050] Furthermore, R5, R6, R7, R9, R8, R 22 , R 23 In the above, the non-cyclic group is selected from hydrogen, halogen, and substituted or unsubstituted C1-3 alkyl.
[0051] Furthermore, R5, R6, R7, R9, R8, R 22 , R 23 In the above, the uncyclic ones are all selected from H.
[0052] Further, it has a structure represented by formula (IV) or its tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, a pharmaceutically acceptable hydrate, solvate or salt:
[0053]
[0054] in:
[0055] n is selected from 0, 1 or 2;
[0056] R2 is selected from halogen;
[0057] R4, R9, R 10 , R 11 , R 14 Each of the substituents is independently selected from hydrogen, halogen, hydroxyl, cyano, amino, substituted or unsubstituted C1-6 alkyl or heteroalkyl, substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxyl, cyano, amino, ester, amide, and sulfonyl;
[0058] R5, R6, R 22 , R 23 Each of them is independently selected from hydrogen, halogen, substituted or unsubstituted C1-6 alkyl or heteroalkyl, substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl;
[0059] or R5, R6 and the carbon atom to which they are connected constitute a substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl;
[0060] The heterocycloalkyl group contains one or more O or NR 25 , the substituents are independently selected from halogen, hydroxyl, cyano, amino, ester, amide, and sulfonyl;
[0061] or R5, R9 and the carbon atom and nitrogen atom to which they are respectively connected together form a substituted or unsubstituted C3-6 N heterocycloalkyl group, or R 23 , R9 and the carbon atoms, nitrogen atoms and saturated segments of macrocyclic molecules between carbon atoms and nitrogen atoms to which they are respectively connected together constitute a substituted or unsubstituted C3-6 N heterocycloalkyl, wherein the substituents are independently selected from halogen, C1-6 alkyl or heteroalkyl, hydroxyl, cyano, amino and ester groups;
[0062] R 25 Selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-6 cycloalkyl, wherein the substituent is selected from halogen, hydroxyl, cyano, and amino.
[0063] Further, R4 is selected from H, halogen, hydroxyl, substituted or unsubstituted C1-6 alkyl or heteroalkyl, substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxyl, cyano, amino, ester, amide, sulfonyl;
[0064] R5, R6, R 22 , R 23 , R9 are independently selected from H, halogen, C1-3 alkyl;
[0065] or R5, R6 and the carbon atoms connected thereto form a substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, wherein the heterocycloalkyl contains one or more O or NR 25 , the substituents are independently selected from F, Cl, Br, hydroxyl, cyano, and amino;
[0066] or R5, R9 and the carbon atom and nitrogen atom to which they are respectively connected together form a C3-6 N-heterocycloalkyl group, or R 23 , R9 and the carbon atom, nitrogen atom and saturated chain segments of macrocyclic molecules between carbon atoms and nitrogen atoms respectively connected thereto together form a C3-6 N heterocycloalkyl group;
[0067] R 25 Selected from hydrogen, substituted or unsubstituted C1-3 alkyl, wherein the substituents are independently selected from hydroxyl or amino.
[0068] Further: R 10 , R 11 , R 14 is selected from H, halogen, substituted or unsubstituted C1-6 alkyl or heteroalkyl; further, R 10 , R 11 , R 14 Selected from H.
[0069] In a specific embodiment of the present invention, R4 is selected from H, F, Cl, Br, methyl, trifluoromethyl, difluoromethyl, methoxy, ethyl, propyl, isopropyl, cyclopropyl, hydroxyl, In a specific embodiment of the present invention, n is selected from 0 or 1.
[0070] Furthermore, R5, R6, R9, R 22 , R 23 There is at least one loop between any two of them.
[0071] Furthermore, R5, R6, R9, R 22 , R 23 There is only one possible loop between any two pairs.
[0072] Furthermore, R5, R6, R9, R 22 , R 23 In the above, the uncyclic ones are all selected from H.
[0073] Further, R5, R6 and the carbon atoms to which they are connected constitute a substituted or unsubstituted C3-6 cycloalkyl group, or R5, R9 and the carbon atoms and nitrogen atoms to which they are respectively connected constitute a substituted or unsubstituted 4-6 membered N-containing heterocycloalkyl group, wherein n is selected from 0; further, R5, R6 and the carbon atoms to which they are connected constitute a substituted or unsubstituted cyclopropyl group, or R5, R9 and the carbon atoms and nitrogen atoms to which they are respectively connected constitute a substituted or unsubstituted 5 membered N-containing heterocycloalkyl group.
[0074] Further,
[0075] for Furthermore, the for Further, it has a structure represented by formula (V) or its tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, a pharmaceutically acceptable hydrate, solvate or salt:
[0076]
[0077] in:
[0078] n is selected from 0, 1 or 2;
[0079] R2 is selected from halogen;
[0080] R4, R9, R 10 , R 11 , R 14Each of the substituents is independently selected from hydrogen, halogen, hydroxyl, cyano, amino, substituted or unsubstituted C1-6 alkyl or heteroalkyl, substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxyl, cyano, amino, ester, amide, and sulfonyl;
[0081] R 23 Selected from hydrogen, halogen, substituted or unsubstituted C1-6 alkyl or heteroalkyl, substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl;
[0082] R5, R8, the carbon atoms to which they are connected, and the saturated chain segments of the macrocyclic molecules between the two carbon atoms together constitute a substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, wherein the heterocycloalkyl contains one or more O or NR 25 , the substituents are independently selected from halogen, hydroxyl, cyano, amino, ester, amide, and sulfonyl;
[0083] R 25 Selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-6 cycloalkyl, wherein the substituent is selected from halogen, hydroxyl, cyano, and amino.
[0084] Further, R4 is selected from H, halogen, hydroxyl, substituted or unsubstituted C1-6 alkyl or heteroalkyl, substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxyl, cyano, amino, ester, amide, sulfonyl;
[0085] R9 is selected from H, C1-3 alkyl or heteroalkyl;
[0086] R 23 Selected from H, halogen, C1-3 alkyl;
[0087] R5, R8, the carbon atoms to which they are connected, and the saturated chain segments of the macrocyclic molecules between the two carbon atoms together constitute a substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, wherein the heterocycloalkyl contains one or more O or NR 25 , the substituents are independently selected from F, Cl, Br, hydroxyl, cyano, and amino;
[0088] R 25 Selected from hydrogen, substituted or unsubstituted C1-3 alkyl, wherein the substituents are independently selected from hydroxyl or amino.
[0089] Furthermore, R 10 , R 11 , R 14 Selected from H, halogen, substituted or unsubstituted C1-6 alkyl or heteroalkyl.
[0090] Furthermore, R10 , R 11 , R 14 Selected from H.
[0091] In a specific embodiment of the present invention, R4 is selected from H, F, Cl, Br, methyl, trifluoromethyl, difluoromethyl, methoxy, ethyl, propyl, isopropyl, cyclopropyl, hydroxyl,
[0092] Furthermore, R5, R8, the carbon atoms to which they are respectively connected and the saturated chain segment of the macrocyclic molecule between two carbon atoms together constitute a substituted or unsubstituted C3-6 cycloalkyl group, and the substituents are independently selected from F, Cl, Br, hydroxyl, cyano, and amino; Y is O.
[0093] Furthermore, R5, R8, the carbon atoms to which they are respectively connected, and the saturated chain segment of the macrocyclic molecule between the two carbon atoms together constitute a substituted or unsubstituted cyclobutyl, cyclopentyl, or cyclohexyl group, preferably a cyclopentyl or cyclohexyl group.
[0094] Further,
[0095] for Further
[0096] Furthermore, n is selected from 0 or 1.
[0097] Furthermore, R4 is selected from H and halogen.
[0098] In a specific embodiment of the present invention, the compound structure is selected from one of the following:
[0099]
[0100]
[0101]
[0102]
[0103] The present invention also provides a pharmaceutical composition, wherein the active ingredient of the pharmaceutical composition is selected from one or a combination of two or more of the aforementioned compounds or their stereoisomers, solvates, hydrates, pharmaceutically acceptable salts or co-crystals.
[0104] In addition to the aforementioned compounds, the pharmaceutical composition may also include at least one additional therapeutic agent. The additional therapeutic agent may be selected from immunomodulators, cancer chemotherapy drugs, anti-infective drugs, etc. The cancer chemotherapy drugs include but are not limited to alkylating agents (such as nitrogen mustard), nucleoside analogs (such as gemcitabine), nitrosoureas (such as carmustine), platinum drugs (such as cisplatin), DNA breakers (such as bleomycin), antimetabolites (folate antagonists such as methotrexate, pyrimidine antagonists such as fluorouracil, purine antagonists such as pentostatin, etc.), microtubule protein interactors (such as vincristine, docetaxel, etc.), hormones, etc.
[0105] The present invention also provides the use of the above-mentioned compound or its stereoisomers, solvates, hydrates, pharmaceutically acceptable salts or cocrystals in the preparation of protein kinase inhibitors; further, the kinase inhibitor is selected from one or more of ALK inhibitors, ROS1 inhibitors, TRK inhibitors, MET inhibitors, JAK inhibitors, and CSF-1R inhibitors.
[0106] The present invention also provides the use of the above-mentioned compound or its stereoisomers, solvates, hydrates, pharmaceutically acceptable salts or co-crystals in the preparation of drugs for treating pain, cancer, inflammation, autoimmune diseases, neurodegenerative disorders or Trypanosoma cruzi infection in mammals.
[0107] Furthermore, the cancer is selected from: non-small cell lung cancer, gastric cancer, neuroblastoma, lung cancer, ovarian cancer, appendix cancer, colorectal cancer, melanoma, cancer of the head and neck, breast cancer, glioblastoma, medulloblastoma, secretory breast cancer, papillary thyroid cancer, adult myeloid leukemia, pancreatic cancer, prostate cancer, bile duct cancer, salivary gland cancer, gastrointestinal stromal tumor, infantile fibrosarcoma.
[0108] The present invention also provides the use of the above compound or its stereoisomer, solvate, hydrate, pharmaceutically acceptable salt or co-crystal in preparing a drug for inhibiting cell proliferation.
[0109] The present invention also provides the use of the above-mentioned compound or its stereoisomers, solvates, hydrates, pharmaceutically acceptable salts or co-crystals in the preparation of drugs for treating diseases that cause overexpression of ALK, ROS1, TRK, MET, JAK, CSF-1R kinases.
[0110] The present invention also provides the use of the above-mentioned compound or its stereoisomers, solvates, hydrates, pharmaceutically acceptable salts or co-crystals in the preparation of drugs for treating diseases caused by overexpression of ALK, ROS1, TRK, MET, JAK, CSF-1R kinases.
[0111] The present invention also provides a method for preparing the above compound, comprising the following contents:
[0112]
[0113] (1) Compound a and compound b are reacted under the action of a base to generate compound c, and then the substituent R 28 Removal gives compound d;
[0114] Among them, R 28 Selected from benzyl, silyl, p-methoxybenzyl, 2,4-dimethoxybenzyl, allyl, acyl, C1-3 alkyl;
[0115] (2) Compound d and compound e are reacted to generate compound f by dehydrating two hydroxyl molecules to form an ether;
[0116] (3) removing the Boc protecting group from compound f under acidic conditions to generate compound g;
[0117] (4) hydrolyzing compound g under the action of a base to generate compound h;
[0118] (5) Compound h is reacted with a base and a condensation reagent to generate compound i.
[0119] In a specific embodiment of the present invention, in step (2), compound f is generated by Mitsunobu reaction. The present invention also provides another method for preparing the above compound, comprising the following contents:
[0120]
[0121] (1) Substituent R of compound j 28 Removing the compound k, and then reacting the compound k with the compound b under the action of a base to generate the compound m;
[0122] Among them, R 29 Selected from benzyl, silyl, p-methoxybenzyl, 2,4-dimethoxybenzyl, allyl, acyl, C1-3 alkyl;
[0123] (2) Compound m and compound n undergo condensation reaction under the action of a base to generate compound o.
[0124] (3) removing the Boc protecting group from compound o under acidic conditions to generate compound p;
[0125] (4) hydrolyzing compound p under the action of a base to generate compound h;
[0126] (5) Compound h is reacted with a base and a condensation reagent to generate compound r.
[0127] The present invention also provides another method for preparing the above compound, comprising the following contents:
[0128]
[0129] (1) reacting compound s with compound t to generate compound u;
[0130] (2) Compound u is hydrogenated to form compound v;
[0131] (3) removing the Boc protecting group from compound v under acidic conditions to generate compound w;
[0132] (4) reacting compound w with compound b under the action of a base to generate compound x;
[0133] (5) hydrolyzing compound x under the action of a base to generate compound y;
[0134] (5) reacting compound y with a base and a condensation reagent to generate compound z;
[0135] Among them, R 30 Selected from Cl, Br, I, OTf.
[0136] The present invention also provides another method for preparing the above compound, comprising the following contents:
[0137] (1) reacting compound aa with compound t to generate compound ab;
[0138] (2) Compound ab undergoes hydrogenation to generate compound ac;
[0139] (3) removing the Boc protecting group from compound ac under acidic conditions to generate compound ad;
[0140] (4) reacting compound ad with compound b under the action of a base to generate compound ae;
[0141] (5) hydrolyzing compound ae under the action of a base to generate compound af;
[0142] (5) Compound af is reacted with a base and a condensation reagent to generate compound ag;
[0143] Among them, R 31 Selected from Br, I, OTf.
[0144] The present invention also provides compound VI, whose structural formula is as follows:
[0145]
[0146] Among them, R 19 Selected from halogen, NR 20 , OR 20 , R 20 Selected from Boc, benzyl, p-methoxybenzyl, 2,4-dimethoxybenzyl, methyl, allyl, trimethylsilyl.
[0147] The present invention also provides a method for preparing compound VI, comprising the following contents:
[0148] Mix 5-fluoro-2-methoxynicotinonitrile, tetraisopropyl titanate and a solvent, and add ethylmagnesium bromide to the mixture in a nitrogen or inert gas atmosphere at -80°C to -50°C, preferably -70°C;
[0149] Based on the molar amount of 5-fluoro-2-methoxynicotinonitrile, the amount of tetraisopropyl titanate is 1 to 2 equivalents, preferably 1 to 1.5 equivalents; the amount of Grignard reagent is 1.5 to 3 equivalents, preferably 2 to 2.5 equivalents.
[0150] Furthermore, the solvent is selected from one or more of tetrahydrofuran, diethyl ether and toluene, preferably tetrahydrofuran.
[0151] Furthermore, ethylmagnesium bromide is added in batches, preferably dropwise.
[0152] Furthermore, after the addition of the Grignard reagent, the reaction is carried out at the original low temperature for 5 to 30 minutes, preferably 10 to 15 minutes; and then the reaction system is heated to room temperature for reaction.
[0153] Furthermore, the post-treatment method is: after mixing the reaction system with 1 to 4 equivalents of boron trifluoride etherate, adding dilute hydrochloric acid to quench the reaction; further, the amount of boron trifluoride etherate used is 2 to 3 equivalents.
[0154] The present invention also provides compound VII, whose structural formula is as follows:
[0155]
[0156] Among them, R 21 Selected from H, fluorine, chlorine, bromine, methyl, trifluoromethyl, difluoromethyl, methoxy, ethyl, isopropyl, cyclopropyl.
[0157] The present invention also provides a method for preparing compound VII, comprising the following contents:
[0158] (1) 2-fluoromalonic acid, 5-amino-1H-pyrazole-4-carboxylic acid ethyl ester, POCl3, DMF, and N,N-diethylaniline are mixed and reacted at 80 to 100°C to obtain 5,7-dichloro-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester; based on the molar amount of 2-fluoromalonic acid, the amount of 5-amino-1H-pyrazole-4-carboxylic acid ethyl ester is 0.8 to 1.5 equivalents, preferably 1 equivalent; the amount of N,N-diethylaniline is 0.8 to 1.5 equivalents, preferably 1 equivalent;
[0159] (2) 5,7-dichloro-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester, zinc powder, NH4Cl and a solvent are mixed; the solvent is a mixed solvent of EtOH:THF:water=2-4:1:1.5-2.5; the solvent is a mixed solvent of EtOH:THF:water=3:1:2; based on the molar amount of 5,7-dichloro-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester, the amount of zinc powder is 1-2 equivalents, preferably 1-1.5 equivalents; the amount of NH4Cl is 2-3 equivalents, preferably 2.5-3 equivalents.
[0160] Furthermore, the amount of POCl3 used is: 0.5-1.5 mL POCl3 per mmol of 2-fluoromalonic acid, preferably 1 mL; the amount of N,N-diethylaniline used is: 0.1-0.5 mL N,N-diethylaniline per mmol of 2-fluoromalonic acid, preferably 0.2 mL.
[0161] Furthermore, in step (2), the amount of solvent used is: 10 to 20 mL of solvent per millimole of ethyl 5,7-dichloro-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate, preferably 15 to 18 mL.
[0162] The present invention also provides the use of compound VI and compound VII in preparing the above compounds.
[0163] The "equivalent" mentioned in the present invention refers to the molar ratio between compounds. For example, "based on the molar amount of 5-fluoro-2-methoxynicotinonitrile, the amount of tetraisopropyl titanate is 1 to 2 equivalents", which means that the amount (molar amount) of tetraisopropyl titanate is 1 to 2 times the amount (molar amount) of 5-fluoro-2-methoxynicotinonitrile, and so on.
[0164] The pharmaceutical composition containing the compound of the present invention or its stereoisomer, solvate, hydrate, pharmaceutically acceptable salt or co-crystal may contain a pharmaceutically acceptable excipient.
[0165] The term "pharmaceutically acceptable" as used herein refers to any substance that does not interfere with the effectiveness of the biological activity of the active ingredient and is non-toxic to the host to which it is administered.
[0166] The pharmaceutically acceptable excipients described in the present invention are a general term for all additional materials in the drug except the main drug. The excipients should have the following properties: (1) no toxic effects on the human body and almost no side effects; (2) stable chemical properties, not easily affected by temperature, pH, storage time, etc.; (3) no incompatibility with the main drug, and no impact on the efficacy and quality inspection of the main drug; (4) no interaction with the packaging material. The excipients in the present invention include but are not limited to fillers (diluents), lubricants (glidants or anti-adhesive agents), dispersants, wetting agents, adhesives, regulators, solubilizers, antioxidants, antibacterial agents, emulsifiers, disintegrants, etc. Binders include syrup, gum arabic, gelatin, sorbitol, tragacanth, cellulose and its derivatives (such as microcrystalline cellulose, sodium carboxymethyl cellulose, ethyl cellulose or hydroxypropyl methyl cellulose, etc.), gelatin slurry, syrup, starch slurry or polyvinyl pyrrolidone, etc.; fillers include lactose, powdered sugar, dextrin, starch and its derivatives, cellulose and its derivatives, inorganic calcium salts (such as calcium sulfate, calcium phosphate, calcium hydrogen phosphate, precipitated calcium carbonate, etc.), sorbitol or glycine, etc.; lubricants include micropowder silica gel, magnesium stearate, talc, aluminum hydroxide, boric acid, hydrogenated vegetable oil, polyethylene glycol, etc.; disintegrants include starch and its derivatives (such as sodium carboxymethyl starch, sodium starch glycolate , pregelatinized starch, modified starch, hydroxypropyl starch, corn starch, etc.), polyvinyl pyrrolidone or microcrystalline cellulose, etc.; wetting agents include sodium dodecyl sulfate, water or alcohol, etc.; antioxidants include sodium sulfite, sodium bisulfite, sodium pyrosulfite, dibutyl benzoic acid, etc.; antibacterial agents include 0.5% phenol, 0.3% cresol, 0.5% chlorobutanol, etc.; regulators include hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium citrate and buffers (including sodium dihydrogen phosphate and disodium hydrogen phosphate), etc.; emulsifiers include polysorbate-80, sorbitan monophosphate, Pluronic F-68, lecithin, soybean lecithin, etc.; solubilizers include Tween-80, bile, glycerol, etc. The term "pharmaceutically acceptable salt" refers to salts formed by the compounds of the present invention and acids or bases that are suitable for use as drugs. The above acids and bases are Lewis acids and bases in a broad sense. Acids suitable for forming salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenesulfonic acid, benzenesulfonic acid, and the like; and acidic amino acids such as aspartic acid and glutamic acid.
[0167] The administration method of the compound or pharmaceutical composition of the present invention is not particularly limited, and representative administration methods include (but are not limited to): oral, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
[0168] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0169] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.
[0170] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances, etc.
[0171] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0172] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances, and the like.
[0173] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0174] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.
[0175] The compounds of the present invention can also be used in injection preparations, wherein the injection is selected from liquid injection (water injection), sterile powder for injection (powder injection) or injection tablets (referring to molded tablets or machine-pressed tablets made by aseptic operation of drugs, dissolved in injection water before use, for subcutaneous or intramuscular injection).
[0176] The powder for injection contains at least an excipient in addition to the above-mentioned compound. The excipient in the present invention is a component intentionally added to the drug, which should not have pharmacological properties in the amount used, but the excipient can help the processing, dissolution or dissolution of the drug, delivery of the drug through a targeted administration route or stability.
[0177] "Alkyl" refers to an aliphatic hydrocarbon group, which refers to a saturated hydrocarbon group. The alkyl portion may be a straight chain alkyl group or a branched chain alkyl group.
[0178] The C1-n used in the present invention includes C1-2, C1-3 ... C1-n. n is an integer greater than 1. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like.
[0179] "Amide" is a chemical structure having the formula -C(O)NHR or -NHC(O)R, where R is selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl.
[0180] "Ester" refers to a chemical structure having the formula -COOR, where R is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl.
[0181] "Ring" refers to any covalently closed structure, including, for example, a carbocyclic ring (e.g., an aryl or cycloalkyl group), a heterocyclic ring (e.g., a heteroaryl or heterocycloalkyl group), an aromatic group (e.g., an aryl or heteroaryl group), a non-aromatic group (e.g., a cycloalkyl or heterocycloalkyl group). The ring may be optionally substituted and may be a monocyclic or polycyclic ring. Typical polycyclic rings generally include bicyclic and tricyclic rings.
[0182] "Member" refers to the number of skeleton atoms constituting the ring. Typical 5-membered rings include cyclopentyl, pyrrole, imidazole, thiazole, furan, and thiophene; typical 6-membered rings include cyclohexyl, pyridine, pyran, pyrazine, thiopyran, pyridazine, pyrimidine, benzene, etc. Among them, a ring containing heteroatoms in the skeleton atoms is a heterocycle; an aromatic group composed of a heterocycle is a heteroaryl group; a non-aromatic group composed of a heterocycle is a heterocycloalkyl group.
[0183] "Heteroalkyl" refers to an alkyl group containing heteroatoms, where the heteroatoms include but are not limited to O, S, N, P, etc.; alkoxy, sulfanyl, aminoalkyl, etc. are all heteroalkyl groups.
[0184] The heteroalkyl or heterocycloalkyl of "C1-n", wherein n is an integer greater than one, refers to the number of carbon atoms in the heteroalkyl or the number of carbon atoms in the skeleton of the heterocycloalkyl ring.
[0185] Typical heterocycloalkyl groups include, but are not limited to:
[0186]
[0187] Typical heteroaryl or heteroaromatic groups include, but are not limited to:
[0188]
[0189] "Aromatic" means a planar ring with a delocalized π electron system and containing 4n+2 π electrons, where n is an integer. The aromatic ring may be composed of five, six, seven, eight, nine, or more than nine atoms. Aromatic groups include, but are not limited to, phenyl, naphthyl, phenanthrenyl, anthracenyl, fluorenyl, and indenyl.
[0190] "Cycloalkyl" refers to a monocyclic or polycyclic group containing only carbon and hydrogen and may be saturated or unsaturated. Typical cycloalkyl structures include, but are not limited to:
[0191]
[0192] "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine. "Haloalkyl" refers to an alkyl group in which at least one hydrogen atom is replaced by a halogen atom.
[0193] The present invention also has the following expression: R5, R8, the carbon atoms to which they are respectively connected, and the saturated chain segment of the macrocyclic molecule between the two carbon atoms together constitute a substituted or unsubstituted monocyclic, bicyclic or tricyclic C3-10 cycloalkyl or heterocycloalkyl; or R 23, R9 and the carbon atoms, nitrogen atoms and saturated segments of macrocyclic molecules between carbon atoms and nitrogen atoms connected thereto, together constitute a substituted or unsubstituted C3-10 heterocyclic alkyl group. The explanation of the "saturated segments of macrocyclic molecules" is as follows: Since the compound of the present invention is a macrocyclic compound, the macrocyclic chain "between two carbon atoms" or "between carbon atoms and nitrogen atoms" as mentioned above has two segments, one is long and the other is relatively short. According to the structural formula, it can be seen that the relatively short segment is a saturated bond. Therefore, the shorter segment of the macrocyclic chain is defined as a saturated segment of the macrocyclic molecule.
[0194] For example:
[0195] In the compound shown in formula (I), R5, R8 and the carbon atoms to which they are respectively connected and the saturated chain segment of the macrocyclic molecule between the two carbon atoms together constitute a substituted or unsubstituted monocyclic, bicyclic or tricyclic C3-10 cycloalkyl or heterocycloalkyl,
[0196] Right now In this section, R5, R8 and the carbon atom to which they are connected are 22 R 23 )- n The carbon chains on the macrocyclic molecule are combined to form substituted or unsubstituted monocyclic, bicyclic or tricyclic C3-10 cycloalkyl or heterocycloalkyl groups, such as And so on.
[0197] The amino group, ester group, carbonyl group, amide group, etc. mentioned herein may be an unsubstituted amino group, ester group, carbonyl group, amide group, or a substituted amino group, ester group, carbonyl group, amide group.
[0198] In the above, unless otherwise specified, the "substituted" in the "substituted or unsubstituted" means that the mentioned group can be substituted by one or more additional groups, and the additional groups are each and independently selected from alkyl, cycloalkyl, aryl, carboxyl, heteroaryl, heterocycloalkyl, hydroxy, alkoxy, alkylthio, aryloxy, nitro, acyl, halogen, haloalkyl, amino and the like.
[0199] "Inhibitor" refers to a substance that reduces the activity of an enzyme.
[0200] Obviously, according to the above contents of the present invention, in accordance with the common technical knowledge and means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0201] The above contents of the present invention are further described in detail below in the form of specific embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following embodiments. All technologies realized based on the above contents of the present invention belong to the scope of the present invention.
[0202] The beneficial effects of the present invention are:
[0203] (1) The present invention provides a series of compounds that have the ability to inhibit the activity of ALK, ROS1, and TRK kinases. Experiments have shown that they have a significant inhibitory effect on the activity of protein kinase inhibitors, providing a new approach for the treatment of diseases that target protein kinases, such as mammalian pain, cancer, inflammation, autoimmune diseases, neurodegenerative disorders, Trypanosoma cruzi infection, and the like.
[0204] (2) Compared with TPX-0005 in Phase II clinical trials, the compound of the present invention has obvious advantages in pharmacokinetic aspects and can be used as a protein kinase inhibitor, with broad application prospects in the treatment of malignant tumors or inflammatory diseases. DETAILED DESCRIPTION
[0205] The technical solution of the present invention is described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0206] In the examples, the following abbreviations have the following meanings:
[0207] NMP: N-methylpyrrolidone;
[0208] EA: ethyl acetate;
[0209] M refers to the molar concentration unit mol / L, for example 1M means 1 mol / L;
[0210] THF: tetrahydrofuran;
[0211] N refers to the normal concentration, for example, 1N HCl refers to hydrochloric acid with a concentration of 1 mol / L;
[0212] MTBE: methyl tert-butyl ether;
[0213] POCl3: phosphorus oxychloride;
[0214] DMF: N,N-dimethylformamide;
[0215] TLC: thin layer chromatography;
[0216] PE refers to petroleum ether (boiling point 60-90°C);
[0217] DCM: dichloromethane;
[0218] H2O: distilled water;
[0219] DIEA: N,N-diisopropylethylamine;
[0220] TMSCl: trimethylchlorosilane;
[0221] DIAD: diisopropyl azodicarboxylate;
[0222] Dioxane: 1,4-dioxane;
[0223] HATU: O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate;
[0224] TsCl: p-toluenesulfonyl chloride;
[0225] 1,4-dioxane: 1,4-dioxane;
[0226] Pd2(dba)3: 3,3,6,6-tetramethyl-9-(1,2,3,4-tetrahydroxybutyl)-4,5,7,9-tetrahydro-2H-anthracene-1,8-dione);
[0227] X-phos: 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl;
[0228] Xant-phos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene.
[0229] Preparation of intermediates
[0230] Intermediate 1: Preparation of 1-(5-fluoro-2-methoxypyridin-3-yl)cyclopropane-1-amine
[0231]
[0232] Step 1: Preparation of 5-fluoro-2-methoxynicotinonitrile
[0233] 3-Bromo-5-fluoro-2-methoxypyridine (11.0 g, 53.7 mmol) was dissolved in NMP (110 mL), and cuprous cyanide (24.0 g, 268.5 mmol) was added thereto. The mixture was heated to 160°C under N2 protection and stirred for 6 hours. TLC showed that the reaction of the raw material was complete. The solid was filtered and the filter cake was washed with EA. Water (1.1 L) was added to the filtrate, and the solid was filtered out after stirring. The filtrate was extracted twice with EA, the filtrate was combined and dried over anhydrous Na2SO4, and concentrated to dryness to obtain a crude product as a brown solid. The solid was dissolved in EA (20 mL), and petroleum ether (200 mL) was slowly added thereto to precipitate a solid. The precipitated solid was filtered and dried to obtain the target compound (7.3 g, yield 90%) as an off-white solid.
[0234] Step 2: Preparation of 1-(5-fluoro-2-methoxypyridin-3-yl)cyclopropane-1-amine
[0235] 5-Fluoro-2-methoxynicotinonitrile (7.3g, 48.0mmol) and tetraisopropyl titanate (16.4g, 57.6mmol) were dissolved in anhydrous tetrahydrofuran (80mL), the reaction system was replaced with N2 and cooled to -70°C. Ethylmagnesium bromide (106mL, 106mmol, 1M in THF) was slowly added dropwise to the system, and the internal temperature was controlled not to be higher than -65°C. After the addition was completed, the temperature was maintained and the reaction continued for 10 minutes, the low temperature bath was removed and the temperature was slowly restored to room temperature and stirred for 2 hours. Boron trifluoride etherate (13.6g, 96.0mmol) was added to the system and the reaction was quenched with 1N dilute hydrochloric acid, and then the pH was adjusted to 9-10 with NaOH. Filter and concentrate the filtrate to dryness. The residue was purified by column chromatography (PE / EA=10 / 1) using the crude product to obtain the target compound (3.1g, yield 35%) as a yellow solid.
[0236] EM (calculated): 182.1; MS (ESI) m / z (M+H)+: 183.2
[0237] 1 H NMR (400MHz, CDCl3) δ1.05-1.08(2H,m),1.45-1.48(2H,m),4.00(3H,s),7.28(1H,dd,J=8.2Hz,2.8Hz),8.02(1H,d,J=2.8Hz).
[0238] Intermediate 2: Preparation of ethyl 5-chloro-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate
[0239]
[0240] Step 1: Preparation of 2-fluoromalonic acid
[0241] Dissolve NaOH (4.5 g, 113 mmol) in water (25 mL), add EtOH (100 mL) and heat to 60 ° C. Slowly add diethyl 2-fluoromalonate (10.0 g, 56.2 mmol) to the reaction system, and a large amount of white solid precipitates. After 2 hours of stirring and keeping warm, TLC shows that the reaction of the raw material is complete. Filter and spin dry the solid, dissolve the solid in 4N hydrochloric acid, and stir at room temperature for 1 hour. Concentrate the reaction solution to dryness, add MTBE after cooling, filter after stirring, and concentrate the filtrate to dryness to obtain the target compound (6.7 g, yield 98%) as a white solid.
[0242] EM (calculated): 122.0; MS (ESI) m / z (MH)-: 121.0
[0243] Step 2: Preparation of ethyl 5,7-dichloro-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate
[0244] 2-Fluoromalonic acid (3.0 g, 24.6 mmol) and ethyl 5-amino-1H-pyrazole-4-carboxylate (3.8 g, 24.6 mmol) were dissolved in POCl3 (25 mL), DMF (5 mL) and N, N-diethylaniline (3.7 g, 24.6 mmol) were added to the reaction system, and the temperature was raised to 90°C for 6 hours. TLC showed that the reaction of the raw materials was complete. The reaction solution was concentrated to dryness, and a saturated aqueous solution of Na2CO3 was slowly added to the residue, stirred and extracted with DCM 3 times, and the organic phases were combined and dried with anhydrous Na2SO4 and concentrated to dryness. The crude product was purified by column chromatography (PE / EA=10 / 1) to obtain the target compound (870 mg, yield 13%) as a yellow solid.
[0245] EM (calculated): 277.0; MS (ESI) m / z (M+H)+: 278.1
[0246] Step 3: Preparation of ethyl 5-chloro-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate
[0247] Disperse 5,7-dichloro-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (850 mg, 3.1 mmol), zinc powder (212 mg, 3.3 mmol) and NH4Cl (425 mg, 8.0 mmol) in a mixed solvent of EtOH / THF / water (48 mL, 3 / 1 / 2) and stir at room temperature for 20 minutes. TLC showed that the reaction of the raw materials was complete. The reaction solution was filtered and the filtrate was concentrated to dryness to obtain the target compound (750 mg, yield 100%) as a yellow solid.
[0248] EM (calculated): 243.0; MS (ESI) m / z (M+H)+: 244.1
[0249] 1 H NMR (400MHz, d6-DMSO) δ1.44 (3H, t, J = 6.8Hz), 4.44 (2H, q, J = 6.8Hz), 8.59 (1H, s), 8.74 (1H, d, J = 3.2Hz).
[0250] Intermediate 3: Preparation of ethyl 5-((1-(5-fluoro-2-hydroxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0251]
[0252] Step 1: Preparation of ethyl 5-((1-(5-fluoro-2-methoxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0253] The compound 1-(5-fluoro-2-methoxypyridin-3-yl)cyclopropane-1-amine (500 mg, 2.7 mmol) and 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (618 mg, 2.7 mmol) were dissolved in acetonitrile (10 mL), DIEA (697 mg, 5.4 mmol) was added, and the reaction system was stirred at 80°C for 5 h. TLC showed that the raw materials were completely consumed. The reaction system was concentrated to dryness, water was added to the residue, and DCM was extracted 3 times. The organic phases were combined, dried over anhydrous Na2SO4, and then spin-dried. The crude product was purified by column chromatography (DCM / MeOH=100 / 1~20 / 1) to obtain the target compound (620 mg, yield 62%) as a yellow solid.
[0254] EM (calculated): 371.1; MS (ESI) m / z (M+H)+: 372.2
[0255] Step 2: Preparation of ethyl 5-((1-(5-fluoro-2-hydroxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0256] The compound 5-((1-(5-fluoro-2-methoxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (600 mg, 1.6 mmol) was dissolved in DCM (20 mL), and TMSCl (1.7 g, 16.2 mmol) and potassium iodide (2.7 g, 16.2 mmol) were added in sequence, and stirred at room temperature for 3 hours. TLC showed that the starting material was completely consumed. 20% Na2S2O3 aqueous solution was slowly added to the reaction solution, and the organic phase was retained after washing, dried over anhydrous Na2SO4, and concentrated to dryness. The crude product was purified by column chromatography (DCM / MeOH=100 / 1~20 / 1) to obtain the target compound (520 mg, yield was 91%) as a yellow solid.
[0257] EM (calculated): 357.1; MS (ESI) m / z (M+H)+: 358.2
[0258] 1H NMR (400MHz, d6-DMSO) δ1.04-1.10 (4H, m), 1.35 (3H, t, J = 8.0Hz), 4.30 (2H, q, J = 8.0Hz), 6.39 (1H, d, J = 8.0Hz) ,7.48(1H,s),8.16(1H,s),8.20(1H,dd,J=8.0Hz,3.2Hz),8.50(1H,d,J=8.0Hz),8.68(1H,s),11.47(1H,brs).
[0259] Intermediate 4: Preparation of ethyl 6-fluoro-5-((1-(5-fluoro-2-hydroxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0260]
[0261] Step 1: Preparation of ethyl 6-fluoro-5-((1-(5-fluoro-2-methoxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0262] The compound 1-(5-fluoro-2-methoxypyridin-3-yl)cyclopropane-1-amine (328 mg, 1.8 mmol) and 5-chloro-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (437 mg, 1.8 mmol) were dissolved in CH3CN (12 mL), DIEA (697 mg, 5.4 mmol) was added, and the reaction system was stirred at 80°C overnight. TLC showed that the raw materials were completely consumed. The reaction system was concentrated to dryness, water was added to the residue, and DCM was extracted 3 times. The organic phases were combined, dried over anhydrous Na2SO4, and then spin-dried. The crude product was purified by column chromatography (PE / EA / DCM / =10 / 1 / 1) to obtain the target compound (550 mg, yield 79%) as a yellow solid.
[0263] EM (calculated): 389.1; MS (ESI) m / z (M+H)+: 390.2
[0264] Step 2: Preparation of ethyl 6-fluoro-5-((1-(5-fluoro-2-hydroxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0265] The compound 6-fluoro-5-((1-(5-fluoro-2-methoxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (540 mg, 1.4 mmol) was dissolved in DCM (20 mL), TMSCl (1.53 g, 14.0 mmol) and potassium iodide (2.32 g, 14.0 mmol) were added to the solution in sequence, and stirred at room temperature for 3 hours. TLC showed that the starting material was completely consumed. The reaction solution was washed with 10% Na2S2O3, the organic phase was separated and collected, dried over anhydrous Na2SO4, and concentrated to dryness to obtain the target compound (480 mg, yield 91%) as a yellow solid.
[0266] EM (calculated): 375.1; MS (ESI) m / z (M+H)+: 376.2
[0267] 1 H NMR(400MHz,d6-DMSO)δ1.18-1.19(4H,m),1.34(3H,t,J=7.2Hz),4.30(2H,q,J=7.2Hz),7.48(1H,s ),8.17(1H,dd,J=8.4Hz,3.2Hz),8.21(1H,s),8.71(1H,s),9.06(1H,d,J=6.4Hz),11.44(1H,brs).
[0268] Intermediate 5: Preparation of ethyl 5-((1-(5-fluoro-2-hydroxyphenyl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0269]
[0270] Step 1: Preparation of 1-(5-fluoro-2-methoxyphenyl)cyclopropane-1-amine
[0271] The compound 5-fluoro-2-methoxybenzonitrile (5.0g, 33.1mmol) and tetraisopropyl titanate (11.3g, 39.7mmol) were dissolved in anhydrous THF (50mL), and the reaction system was replaced with N2 and cooled to -70°C. Ethyl magnesium bromide (73mL, 73mmol, 1M in THF) was slowly added to the system, and the internal temperature was controlled not to be higher than -65°C. After the addition was completed, the temperature was maintained and the reaction continued for 10 minutes, the low temperature bath was removed and the temperature was slowly restored to room temperature, and stirred for 2 hours. Boron trifluoride etherate (7.1g, 49.7mmol) was added to the system and the reaction was quenched with 1N dilute hydrochloric acid, and then the pH was adjusted to 9-10 with sodium hydroxide. Filter and concentrate the filtrate to dryness. The residue was purified by column chromatography (PE / EA=10 / 1) to obtain the target compound (2.4g, yield 40%) as a yellow liquid.
[0272] EM (calculated): 181.1; MS (ESI) m / z (M+H)+: 182.2
[0273] Step 2: Preparation of 2-(1-aminocyclopropyl)-4-fluorophenol
[0274] The compound 1-(5-fluoro-2-methoxyphenyl)cyclopropane-1-amine (2.3g, 12.7mmol) was dissolved in anhydrous DCM (30mL), and the reaction system was replaced with N2 three times and cooled to -70°C. Boron tribromide (93.6g, 63.5mmol, 17% dichloromethane solution) was slowly added dropwise to the system, and the internal temperature was controlled not to be higher than -60°C. After the addition was completed, the temperature was maintained and the reaction was continued for 20 minutes, the low temperature bath was removed and the temperature was slowly restored to room temperature, and stirred for 2 hours. After the reaction was completed, methanol was slowly added dropwise to the reaction system for quenching, and the reaction solution was concentrated to dryness. The residue was purified by column chromatography (DCM / MeOH=20 / 1) to obtain the target compound (1.1g, yield 52%) as a yellow oil.
[0275] EM (calculated): 167.1; MS (ESI) m / z (M+H)+: 168.2
[0276] Step 3: Preparation of ethyl 5-((1-(5-fluoro-2-hydroxyphenyl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0277] The compound 2-(1-aminocyclopropyl)-4-fluorophenol (500 mg, 3.0 mmol) and 5-chloro-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (675 mg, 3.0 mmol) were dissolved in CH3CN (12 mL), DIEA (774 mg, 6.0 mmol) was added, and the reaction system was stirred at 80°C overnight. TLC showed that the raw materials were completely consumed. The reaction system was concentrated to dryness, water was added to the residue, and DCM was extracted 3 times. The organic phases were combined, dried over anhydrous Na2SO4, and then spin-dried. The crude product was purified by column chromatography (PE / EA / DCM / =10 / 1 / 1) to obtain the target compound (415 mg, yield 39%) as a yellow solid.
[0278] EM (calculated): 356.1; MS (ESI) m / z (M+H)+: 357.2
[0279] 1H NMR(400MHz,d6-DMSO)δ1.07-1.12(4H,m),1.37(3H,t,J=8.0Hz),4.35(2H,q,J=8.0Hz),6.36(1H,d,J=8.0Hz),7.42(1H,s ),8.03(1H,s),8.08(1H,d,J=7.2Hz),8.15(1H,dd,J=7.2Hz,2.4Hz),8.37(1H,d,J=8.0Hz),8.56(1H,s),10.12(1H,brs).
[0280] Intermediate 6: Preparation of ethyl 6-bromo-5-((1-(2-((1-(((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0281] Step 1: Preparation of ethyl 6-bromo-5-((1-(5-fluoro-2-hydroxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0282] The compound 2-(1-aminocyclopropyl)-4-fluorophenol (1.0 g, 6.0 mmol) and ethyl 6-bromo-5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (1.8 g, 6.0 mmol) were dissolved in CH3CN (30 mL), DIEA (930 mg, 7.2 mmol) was added, and the reaction system was stirred at 80°C for 6 h. TLC showed that the raw materials were completely consumed. The reaction system was concentrated to dryness, water was added to the residue, and DCM was extracted 3 times. The organic phases were combined, dried over anhydrous Na2SO4, and then spin-dried. The crude product was purified by column chromatography (PE / EA / DCM / =10 / 1 / 1) to obtain the target compound (940 mg, yield 36%) as a yellow solid.
[0283] EM (calculated): 435.0; MS (ESI) m / z (M+H)+: 436.1
[0284] Step 2: Preparation of ethyl 6-bromo-5-((1-(2-((1-(((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0285] The compound 6-bromo-5-((1-(5-fluoro-2-hydroxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (920 mg, 2.1 mmol), (1-(hydroxymethyl)cyclopropyl)carbamic acid tert-butyl ester (598 mg, 3.2 mmol) and PPh3 (1.1 g, 4.2 mmol) were dissolved in anhydrous THF (30 mL), and the system was replaced three times with N2. DIAD (850 mg, 4.2 mmol) was slowly added to the reaction system, and the system was yellow and clear. After reacting at room temperature for 1 hour, the reaction was completed. The reaction solution was concentrated, and the residue was added to water, extracted twice with ethyl acetate, and the organic phases were combined and dried over anhydrous Na2SO4. The crude product obtained by concentration was purified by column chromatography (DCM / MeOH=30 / 1) to obtain the target compound (523 mg, yield was 41%) as a yellow solid.
[0286] EM (calculated): 604.1; MS (ESI) m / z (M+H)+: 605.2
[0287] Example compounds
[0288] Example 1 5-oxa-2,8-diazepine-4 5 Preparation of 1-fluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclohexa-9-one
[0289]
[0290] Step 1: Preparation of ethyl 5-((1-(2-((1-((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0291] The compound 5-((1-(5-fluoro-2-hydroxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (500 mg, 1.40 mmol), (1-(hydroxymethyl)cyclopropyl)carbamic acid tert-butyl ester (314 mg, 1.68 mmol) and PPh3 (734 mg, 2.80 mmol) were dissolved in anhydrous THF (20 mL), and the system was replaced three times with N2. DIAD (566 mg, 2.80 mmol) was slowly added to the reaction system, and the system was yellow and clear. After reacting at room temperature for 1 hour, the reaction was completed. The reaction solution was concentrated, and the residue was added to water, extracted twice with ethyl acetate, and the organic phases were combined and dried over anhydrous Na2SO4. The crude product obtained by concentration was purified by column chromatography (DCM / MeOH=25 / 1) to obtain the target compound (278 mg, yield was 38%) as a yellow oily solid.
[0292] EM (calculated): 526.2; MS (ESI) m / z (M+H)+: 527.3
[0293] Step 2: Preparation of ethyl 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0294] The compound 5-((1-(2-((1-((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (250 mg, 0.48 mmol) was dissolved in HCl / EA (15 mL) and stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated to dryness. The residue was dissolved in water (15 mL) and extracted three times with EA. The aqueous phase was collected, the pH was adjusted to 8-9 with saturated aqueous sodium carbonate solution, and extracted three times with DCM. The organic phases were combined and dried over anhydrous Na2SO4, and concentrated to obtain the target compound (183 mg, yield 89%) as an off-white solid.
[0295] EM (calculated): 426.2; MS (ESI) m / z (M+H)+: 427.2
[0296] Step 3: Preparation of 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
[0297] The compound 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (175 mg, 0.41 mmol) was dissolved in EtOH / H2O (10 mL / 1 mL), and NaOH (49 mg, 1.23 mmol) was added to the reaction solution, and the temperature was raised to 60°C for overnight reaction. After the reaction was complete, the reaction solution was adjusted to pH 7 with dilute hydrochloric acid. Concentrated to dryness to obtain a crude product as a white solid. The solid was washed with DCM / EtOH (30 mL, 5 / 1), filtered, and the filtrate was concentrated to obtain the target compound (120 mg, yield 74%) as a light yellow oil.
[0298] EM (calculated): 398.2; MS (ESI) m / z (M+H)+: 399.2
[0299] Step 4: 5-oxa-2,8-diazepine-4 5 Preparation of 1-fluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclohexa-9-one
[0300] The compound 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (115 mg, 0.29 mmol), HATU (165 mg, 0.44 mmol) and DIEA (75 mg, 0.58 mmol) were dispersed in THF (20 mL) and stirred at room temperature for 4 hours. After the reaction was completed, the reaction solution was concentrated, and the residue was added to water, extracted twice with DCM, and the organic phases were combined and dried over anhydrous Na2SO4. The crude product obtained by concentration was purified by column chromatography (DCM / MeOH=30 / 1) to obtain the target compound (65 mg, yield was 59%) as a white solid.
[0301] EM (calculated): 380.1; MS (ESI) m / z (M+H)+: 381.2
[0302] 1H NMR(400MHz,d6-DMSO)δ0.79-0.85(2H,m),0.89-0.99(2H,m),1.21-1.31(2 H,m),2.00-2.04(1H,m),2.08-2.12(1H,m),3.63(1H,d,J=10.4Hz),4.72(1H ,d,J=9.2Hz),6.28(1H,d,J=7.6Hz),7.85(1H,dd,J=8.6Hz,2.8Hz),8.02(1H ,s),8.03(1H,d,J=2.8Hz),8.57(1H,d,J=7.6Hz),9.04(1H,s),9.51(1H,s).
[0303] The following example compounds were synthesized according to the method shown in Example 1:
[0304] Table 1
[0305]
[0306]
[0307]
[0308] Example 6 5-Oxa-2,8-diazepine-1 6 , 4 5 Preparation of -difluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclonuphan-9-one
[0309]
[0310] Step 1: Preparation of ethyl 5-((1-(2-((1-((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate
[0311] The compound 6-fluoro-5-((1-(5-fluoro-2-hydroxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (460 mg, 1.23 mmol), (1-(hydroxymethyl)cyclopropyl)carbamic acid tert-butyl ester (346 mg, 1.85 mmol) and PPh3 (645 mg, 2.46 mmol) were dissolved in anhydrous THF (20 mL), and the system was replaced three times with N2. DIAD (497 mg, 2.46 mmol) was slowly added to the reaction system, and the system was yellow and clear. After reacting at room temperature for 1 hour, the reaction was completed. The reaction solution was concentrated, the residue was added to water, extracted twice with ethyl acetate, and the organic phases were combined and dried over anhydrous Na2SO4. The crude product obtained by concentration was purified by column chromatography (DCM / MeOH=25 / 1) to obtain the target compound (294 mg, yield was 44%) as a yellow oily solid.
[0312] EM (calculated): 544.2; MS (ESI) m / z (M+H)+: 545.3
[0313] Step 2: Preparation of ethyl 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate
[0314] The compound 5-((1-(2-((1-((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (280 mg, 0.51 mmol) was dissolved in HCl / EA (15 mL) and stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated to dryness. The residue was dissolved in water (15 mL) and extracted three times with EA. The aqueous phase was collected, the pH was adjusted to 8-9 with saturated aqueous sodium carbonate solution, and extracted three times with DCM. The organic phases were combined and dried over anhydrous Na2SO4, and concentrated to obtain the target compound (193 mg, yield 85%) as an off-white solid.
[0315] EM (calculated): 444.2; MS (ESI) m / z (M+H)+: 445.3
[0316] Step 3: Preparation of 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid
[0317] The compound 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (175 mg, 0.39 mmol) was dissolved in EtOH / H2O (10 mL / 1 mL), and NaOH (47 mg, 1.17 mmol) was added to the reaction solution, and the temperature was raised to 60°C for overnight reaction. After the reaction was complete, the reaction solution was adjusted to pH 7 with dilute hydrochloric acid. Concentrated to dryness to obtain a crude product as a white solid. The solid was washed with DCM / EtOH (30 mL, 5 / 1), filtered, and the filtrate was concentrated to obtain the target compound (123 mg, yield 76%) as a light yellow oil.
[0318] EM (calculated): 416.1; MS (ESI) m / z (M+H)+: 417.2
[0319] Step 45-Oxa-2,8-diazepine-1 6 , 4 5 Preparation of -difluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclonuphan-9-one
[0320] The compound 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid (115 mg, 0.28 mmol), HATU (165 mg, 0.44 mmol) and DIEA (75 mg, 0.58 mmol) were dispersed in THF (20 mL) and stirred at room temperature for 4 hours. After the reaction was completed, the reaction solution was concentrated, and the residue was added to water, extracted twice with DCM, and the organic phases were combined and dried over anhydrous Na2SO4. The crude product obtained by concentration was purified by column chromatography (DCM / MeOH=30 / 1) to obtain the target compound (29 mg, yield was 26%) as a white solid.
[0321] EM (calculated): 398.1; MS (ESI) m / z (M+H)+: 399.2
[0322] 1H NMR(400MHz,d6-DMSO)δ0.81-0.84(2H,m),0.96-0.98(2H,m),1.17-1.20(1 H,m),1.39-1.42(1H,m),2.01-2.07(1H,m),2.09-2.13(1H,m),3.64(1H,d, J=11.2Hz),4.70(1H,d,J=11.2Hz),7.99(1H,dd,J=8.8Hz,2.8Hz),8.04(1H ,d,J=3.2Hz),8.06(1H,s),9.15(1H,d,J=6.4Hz),9.27(1H,s),9.36(1H,s).
[0323] The following example compounds were synthesized by referring to the method shown in Example 6:
[0324] Table 2
[0325]
[0326]
[0327] Example 7 5-Oxa-2,8-diaza-4 4 Preparation of 1-fluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(2,1)-benzo-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclohexanone-9-one
[0328]
[0329] Step 1: Preparation of (1-(tert-butoxycarbonyl)amino)cyclopropyl)methyl 4-methylbenzenesulfonate
[0330] The compound (1-(hydroxymethyl)cyclopropyl)carbamic acid tert-butyl ester (5.0 g, 26.7 mmol) was dissolved in DCM (50 mL), TsCl (5.6 g, 29.4 mmol) and DIEA (5.2 g, 40.1 mmol) were added thereto in sequence, and the reaction was stirred at room temperature overnight. After the reaction was completed, the reaction solution was added to water and separated. The aqueous phase was extracted twice with DCM, and the organic phases were combined and dried over anhydrous Na2SO4. The crude product obtained by concentration was purified by column chromatography (PE / EA=5 / 1) to obtain the target compound (7.3 g, yield 80%) as a white solid.
[0331] EM (calculated): 341.1; MS (ESI) m / z (M+H)+: 342.2
[0332] Step 2: Preparation of ethyl 5-((1-(2-((1-((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluorophenyl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0333] The compound 5-((1-(5-fluoro-2-hydroxyphenyl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (400 mg, 1.1 mmol) was dissolved in DMF (10 mL), and (1-(tert-butoxycarbonyl)amino)cyclopropyl)methyl 4-methylbenzenesulfonate (375 mg, 1.1 mmol) and K2CO3 (304 mg, 2.2 mmol) were added to the reaction in sequence, and the reaction system was stirred at 100°C overnight. Water was added to the reaction solution, and DCM was extracted 3 times. The organic phases were combined and washed with saturated brine, separated and the organic phases were collected, dried over anhydrous Na2SO4, and then spin-dried. The crude product was purified by column chromatography (DCM / MeOH=30 / 1) to obtain the target compound (286 mg, yield 49%) as a yellow solid.
[0334] EM (calculated): 525.2; MS (ESI) m / z (M+H)+: 526.2
[0335] Step 3: Preparation of ethyl 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluorophenyl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0336] The compound 5-((1-(2-((1-((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluorophenyl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (270 mg, 0.51 mmol) was dissolved in HCl / EA (15 mL) and stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated to dryness. The residue was dissolved in water (15 mL) and extracted three times with EA. The aqueous phase was collected, the pH was adjusted to 8-9 with saturated aqueous Na2CO3 solution, and extracted three times with DCM. The organic phases were combined and dried over anhydrous Na2SO4, and concentrated to obtain the target compound (156 mg, yield was 72%) as an off-white solid.
[0337] EM (calculated): 425.2; MS (ESI) m / z (M+H)+: 426.3
[0338] Step 4: Preparation of 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluorophenyl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
[0339] The compound 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluorophenyl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (150 mg, 0.35 mmol) was dissolved in EtOH / H2O (10 mL / 1 mL), and NaOH (56 mg, 1.40 mmol) was added to the reaction solution, and the temperature was raised to 70°C for overnight reaction. After the reaction was complete, the reaction solution was adjusted to pH 7 with dilute hydrochloric acid. Concentrated to dryness to obtain a crude product as a white solid. The solid was washed with DCM / EtOH (30 mL, 5 / 1), filtered, and the filtrate was concentrated to obtain the target compound (103 mg, yield 74%) as a light yellow oil.
[0340] EM (calculated): 397.2; MS (ESI) m / z (M+H)+: 398.2
[0341] Step 5: 5-oxa-2,8-diazepine-4 4 Preparation of 1-fluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(2,1)-benzo-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclohexanone-9-one
[0342] The compound 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluorophenyl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (98 mg, 0.25 mmol), HBTU (144 mg, 0.38 mmol) and DIEA (65 mg, 0.50 mmol) were dispersed in THF (10 mL) and stirred at room temperature for 4 hours. After the reaction was completed, the reaction solution was concentrated, the residue was added to water, extracted twice with DCM, and the organic phases were combined and dried over anhydrous Na2SO4. The crude product obtained by concentration was purified by TLC (DCM / MeOH=20 / 1) to obtain the target compound (19 mg, yield was 20%) as a white solid.
[0343] EM (calculated): 379.1; MS (ESI) m / z (M+H)+: 380.2
[0344] 1H NMR(400MHz,d6-DMSO)δ0.78-0.87(4H,m),0.94-0.97(1H,m),1.28-1.30(1H,m),2 .05-2.08(1H,m),2.12-2.15(1H,m),3.70(1H,d,J=9.2Hz),4.16(1H,d,J=9.2Hz),6 .27(1H,d,J=7.6Hz),6.82(1H,dd,J=9.2Hz,4.8Hz),6.98-7.03(1H,m),7.35(1H,d d,J=10.0Hz,3.2Hz),8.02(1H,s),8.56(1H,d,J=7.6Hz),9.08(1H,s),9.71(1H,s).
[0345] Example 8 5-Oxa-2,8-diaza-4 5 Preparation of 1-fluoro-1(5,3)-pyrazolo[1-a]pyridin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclohexa-9-one
[0346]
[0347] Step 1: Preparation of ethyl 5-((tert-butoxycarbonyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylate
[0348] The compound tert-butyl pyridin-4-ylcarbamate (7.0g, 36.06mmol) was dissolved in acetonitrile (70mL), O-(2,4-dinitrophenyl)hydroxylamine (7.2g, 36.06mmol) was added thereto, and the mixture was stirred at room temperature overnight. The reaction solution was concentrated to dryness to obtain a yellow solid. The solid was dissolved in DMF (100mL), K2CO3 (6.0g, 43.27mmol) and ethyl propiolate (3.5g, 36.06mmol) were added thereto in sequence, and the mixture was stirred at room temperature for 3h. After the reaction was completed, the reaction solution was added to water (1000mL) with stirring, and extracted three times with EA. The organic phases were combined, washed with water and saturated NaCl aqueous solution in sequence, dried over anhydrous sodium sulfate, and concentrated to dryness. The residue was purified by column chromatography (PE / EA=4 / 1) to obtain the target compound (3.3g, yield 30%) as a yellow solid.
[0349] EM (calculated): 305.1; MS (ESI) m / z (M+H)+: 306.2
[0350] Step 2: Preparation of 5-iodopyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester
[0351] The compound 5-((tert-butoxycarbonyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester (3.3 g, 10.82 mmol) was dissolved in DCM (50 mL), cooled and stirred under an ice-water bath, and TFA (15 mL) was added dropwise. After the addition was complete, the ice-water bath was removed, and the mixture was returned to room temperature and stirred for 3 h. After TLC showed that the reaction was complete, the reaction solution was concentrated to dryness to obtain a brown oil.
[0352] The oil was dissolved in concentrated hydrochloric acid (30 mL), and concentrated sulfuric acid (3 mL) was added dropwise under ice bath. NaNO2 (821 mg, 11.90 mmol) was dissolved in water (15 mL), slowly added dropwise to the reaction system, and stirred in an ice-water bath for 15 min. A small amount of urea (50 mg) was added to the reaction system, and stirring was continued for 15 min. KI (2.89 g, 17.31 mmol) solid was added to the reaction system at one time, and the reaction solution was returned to room temperature and stirred for 30 min. The reaction solution was adjusted to pH = 3 with solid NaOH, and extracted with DCM twice. The organic phases were combined and dried with anhydrous sodium sulfate and concentrated to dryness. The residue was purified by column chromatography (PE / EA = 10 / 1 to 7 / 1) to obtain the target compound (2.0 g, yield 58%) as a yellow solid.
[0353] EM (calculated): 316.0; MS (ESI) m / z (M+H)+: 317.1
[0354] Step 3: Preparation of ethyl 5-((1-(5-fluoro-2-methoxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylate
[0355] The compound 5-iodopyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester (2.0g, 6.33mmol), 1-(5-fluoro-2-methoxypyridin-3-yl)cyclopropane-1-amine (1.4g, 7.60mmol), Pd2(dba)3 (577mg, 0.63mmol), X-phos (600mg, 1.26mmol) and cesium carbonate (6.2g, 18.99mmol) were dispersed in toluene (30mL). The reaction bottle was placed in an oil bath preheated to 95°C and stirred for 2h under nitrogen protection. After the reaction was completed, the reaction solution was cooled and filtered, the filter cake was washed with DCM, and the filtrate was concentrated to dryness. The residue was purified by column chromatography (PE / EA=10 / 1~2 / 1) to obtain the target compound (600mg, yield 26%) as a yellow solid.
[0356] EM (calculated): 370.1; MS (ESI) m / z (M+H)+: 371.2
[0357] Step 4: Preparation of ethyl 5-((1-(5-fluoro-2-hydroxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylate
[0358] The compound 5-((1-(5-fluoro-2-methoxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester (600 mg, 1.62 mmol) was dissolved in acetonitrile (15 mL) and stirred at room temperature. KI (2.69 g, 16.2 mmol) and TMSCl (2.69 g, 16.2 mmol) were added thereto in sequence and stirring was continued for 2 h. After the reaction was completed, most of the acetonitrile was concentrated. The residue was dissolved in DCM and washed with Na2SO3 aqueous solution. The organic phase was collected, dried over anhydrous sodium sulfate, and concentrated to dryness. The residue was washed with PE / EA (30 mL, 10 / 1) and dried to obtain the target compound (520 mg, yield 90%) as a yellow solid.
[0359] EM (calculated): 356.1; MS (ESI) m / z (M+H)+: 357.2
[0360] Step 5: Preparation of ethyl 5-((1-(1-(2-((1-((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluoropyridin-3-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylate
[0361] The compound 5-((1-(5-fluoro-2-hydroxypyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester (300 mg, 0.84 mmol), (1-(hydroxymethyl)cyclopropyl)carbamic acid tert-butyl ester (236 mg, 1.26 mmol) and PPh3 (440 mg, 1.68 mmol) were dissolved in anhydrous THF (10 mL), and the system was replaced three times with N2. DIAD (340 mg, 1.68 mmol) was slowly added to the reaction system, and the system was yellow and clear. After reacting at room temperature for 1 hour, the reaction was completed. The reaction solution was concentrated, and the residue was added to water, extracted twice with ethyl acetate, and the organic phases were combined and dried over anhydrous Na2SO4. The crude product obtained by concentration was purified by column chromatography (DCM / MeOH=50 / 1) to obtain the target compound (207 mg, yield was 47%) as a yellow oily solid.
[0362] EM (calculated): 525.2; MS (ESI) m / z (M+H)+: 526.3
[0363] Step 6: Preparation of 5-((1-(2-(((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylic acid
[0364] The compound 5-((1-(1-(2-((1-((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluoropyridin-3-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester (200 mg, 0.38 mmol) was dissolved in HCl / EA (10 mL) and stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated to dryness. The residue was dissolved in EtOH / H2O (11 mL, 10 / 1), and NaOH (152 mg, 3.80 mmol) was added to the reaction solution, and the temperature was raised to 50°C for 4 hours. After the reaction was complete, the reaction solution was adjusted to pH 7 with dilute hydrochloric acid. Concentrated to dryness to obtain a crude product as a white solid. The solid was washed with DCM / EtOH (20 mL, 5 / 1), filtered, and the filtrate was concentrated to obtain the target compound (75 mg, yield 50%) as a light yellow solid.
[0365] EM (calculated): 397.2; MS (ESI) m / z (M+H)+: 398.3
[0366] Step 7: 5-oxa-2,8-diazepine-4 5 Preparation of 1-fluoro-1(5,3)-pyrazolo[1-a]pyridin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclohexa-9-one
[0367] The compound 5-((1-(2-(((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylic acid (75 mg, 0.19 mmol), HATU (144 mg, 0.38 mmol) and DIEA (74 mg, 0.57 mmol) were dispersed in THF (15 mL) and stirred at room temperature for 4 hours. After the reaction was completed, the reaction solution was concentrated, and the residue was added to water, extracted twice with DCM, and the organic phases were combined and dried over anhydrous Na2SO4. The crude product obtained by concentration was purified by column chromatography (DCM / MeOH=30 / 1) to obtain the target compound (27 mg, yield was 38%) as an off-white solid.
[0368] EM (calculated): 379.1; MS (ESI) m / z (M+H)+: 380.2
[0369] 1H NMR(400MHz,d6-DMSO)δ0.79-0.83(1H,m),0.90-1.05(4H,m),1.13-1.21(2H,m ),1.73-1.78(1H,m),3.62(1H,d,J=11.6Hz),4.74(1H,d,J=11.6Hz),6.33(1H,d d,J=7.4Hz,2.4Hz),7.60(1H,s),7.88(1H,s),7.92(1H,dd,J=8.8Hz,2.8Hz),8 .04(1H,d,J=3.2Hz), 8.09(1H,s), 8.28(1H,d,J=2.0Hz), 8.31(1H,d,J=7.6Hz).
[0370] Example 15 5-Oxa-2,8-diazepine-1 6 -Hydroxy-4 5 Preparation of 1-fluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclohexa-9-one
[0371]
[0372] Step 1: Preparation of 5-((1-(2-(((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)-6-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylic acid
[0373] The compound 5-((1-(2-((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (200 mg, 0.45 mmol) was dissolved in EtOH / H2O (10 mL / 5 mL), and NaOH (180 mg, 4.5 mmol) was added to the reaction solution, and the temperature was raised to 80°C for overnight reaction. After the reaction was complete, the reaction solution was adjusted to pH 7 with dilute hydrochloric acid. Concentrated to dryness to obtain a crude product as a white solid. The solid was washed with DCM / EtOH (10 mL, 5 / 1), filtered, and the filtrate was concentrated to obtain the target compound (97 mg, yield 52%) as an off-white solid.
[0374] EM (calculated): 414.1; MS (ESI) m / z (MH)-: 413.0
[0375] Step 2: 5-oxa-2,8-diazepine-1 6 -Hydroxy-4 5Preparation of 1-fluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclohexa-9-one
[0376] The compound 5-((1-(2-(((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)-6-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylic acid (90 mg, 0.22 mmol), HATU (165 mg, 0.44 mmol) and DIEA (85 mg, 0.66 mmol) were dispersed in THF (30 mL) and stirred at room temperature for 4 hours. After the reaction was completed, the reaction solution was concentrated, and the residue was added to water, extracted twice with DCM, and the organic phases were combined and dried over anhydrous Na2SO4. The crude product obtained by concentration was purified by column chromatography (DCM / MeOH=30 / 1) to obtain the target compound (12 mg, yield was 14%) as a white solid.
[0377] EM (calculated): 396.1; MS (ESI) m / z (M+H)+: 397.2
[0378] 1H NMR(400MHz,d6-DMSO)δ0.82-0.84(2H,m),0.96-0.99(2H,m),1.18-1.23(1H,m),1.40-1.43(1H,m),2.07-2.13(2H,m),3 .65(1H,d,J=11.0Hz),4.68(1H,d,J=11.2Hz),7.96-8.04(3H,m),9.14(1H,s),9.25(1H,s),9.38(1H,s),9.56(1H,brs).
[0379] Example 16 5-Oxa-2,8-diazepine-1 6 -Methoxy-4 5 Preparation of 1-fluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclohexa-9-one
[0380]
[0381] The compound 5-oxa-2,8-diazepine-1 6 -Hydroxy-4 5-Fluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclonuphan-9-one (10 mg, 0.03 mmol), CH3I (4 mg, 0.03 mmol) and K2CO3 (8 mg, 0.06 mmol) were dispersed in acetonitrile (2 mL) and stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was concentrated and the residue was purified by TLC (DCM / MeOH=40 / 1) to obtain the target compound (3 mg, yield was 24%) as a white solid.
[0382] EM (calculated): 410.2; MS (ESI) m / z (M+H)+: 411.2
[0383] 1H NMR(400MHz,d6-DMSO)δ0.80-0.84(2H,m),0.93-0.99(2H,m),1.25-1.34(2H,m),2.09-2.20(2H,m),3.67(1H, d,J=11.0Hz),3.95(3H,s),4.73(1H,d,J=11.2Hz),7.93-8.00(3H,m),9.12(1H,s),9.20(1H,s),9.36(1H,s).
[0384] Example 17 5-Oxa-2,8-diazepine-1 6 -Dimethylphosphoryl-4 5 Preparation of 1-fluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclohexa-9-one
[0385]
[0386] Step 1: Preparation of ethyl 5-((1-(1-(2-((1-((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)aminoethyl-6-(dimethylphosphoryl)pyrazolo[1,5-a]pyrimidine-3-carboxylate
[0387] The compound 6-bromo-5-((1-(2-((1-(((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluoropyridin-3--3-yl)cyclopropyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (100 mg, 0.17 mmol), dimethylphosphine oxide (53 mg, 0.68 mmol), Pd2(dba)3 (18 mg, 0.02 mmol), xant-phos (23 mg, 0.04 mmol) and Et3N (52 mg, 0.51 mmol) were dispersed in 1,4-dioxane (5 mL) and reacted at 100° C. overnight under nitrogen protection. After the reaction was completed, the reaction solution was concentrated and the residue was purified by column chromatography (DCM / MeOH=40 / 1) to obtain the target compound (77 mg, yield 75%) as an off-white solid.
[0388] EM (calculated): 602.2; MS (ESI) m / z (M+H)+: 603.2
[0389] Step 2: Preparation of 5-((1-(2-(((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)-6-(dimethylphosphoryl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
[0390] The compound 5-((1-(1-(2-((1-((tert-butoxycarbonyl)amino)cyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)aminoethyl-6-(dimethylphosphoryl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (75 mg, 0.12 mmol) was dissolved in HCl / EA (10 mL) and stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated to dryness. The residue was dissolved in EtOH / H2O (11 mL, 10 / 1), and NaOH (20 mg, 0.48 mmol) was added to the reaction solution, and the temperature was raised to 60°C for 4 hours. After the reaction was complete, the reaction solution was concentrated to dryness to obtain a crude product as a white solid. The solid was washed with DCM / EtOH (20 mL, 5 / 1), filtered, and the filtrate was concentrated to obtain the target compound (39 mg, yield 68%) as a light yellow solid.
[0391] EM (calculated): 474.2; MS (ESI) m / z (M+H)+: 475.2
[0392] Step 3: Preparation of 5-oxa-2,8-diaza-16-dimethylphosphoryl-45-fluoro-1(5,3)-pyrazolo[1,5-a]pyrimidin-4(3,2)-pyridin-3(1,1)-cyclopropane-7(1,1)-cyclopropaneheterocyclonofan-9-one
[0393] 5-((1-(2-(((1-aminocyclopropyl)methoxy)-5-fluoropyridin-3-yl)cyclopropyl)amino)-6-(dimethylphosphoryl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (39 mg, 0.08 mmol), HATU (61 mg, 0.16 mmol) and DIEA (21 mg, 0.16 mmol) were dispersed in THF (10 mL) and stirred at room temperature for 4 hours. After the reaction was completed, the reaction solution was concentrated, and the residue was added to water, extracted twice with DCM, and the organic phases were combined and dried over anhydrous Na2SO4. The crude product obtained by concentration was purified by TLC (DCM / MeOH=20 / 1) to obtain the target compound (8 mg, yield was 22%) as an off-white solid.
[0394] EM (calculated): 456.1; MS (ESI) m / z (M+H)+: 457.1
[0395] 1 H NMR(400MHz,d6-DMSO)δ0.83-0.87(4H,m),0.93-0.98(1H,m),1.28-1.30(1H,m ),1.83(3H,s),1.85(3H,s),2.03-2.07(1H,m),2.10-2.14(1H,m),3.58(1H,d,J =9.0Hz), 4.12 (1H, d, J = 9.0Hz), 7.99 (1H, dd, J = 6.8Hz, 2.8Hz), 8.01 (1H, d, J = 1 1.6Hz),8.05(1H,d,J=6.8Hz),9.15(1H,d,J=6.4Hz),9.27(1H,s),9.36(1H,s).
[0396] The following example compounds were synthesized by referring to the method shown in Example 17:
[0397] Table 3
[0398]
[0399]
[0400] Experimental Example 1 Inhibitory effect of compounds on kinase activity
[0401] 1: Test materials:
[0402] ALK(Carna,No.11CBS-0934L),ALK L1196M(Carna,No.15CBS-0496E),TRKA(Carna,No.13CBS-0565G),ROS1(Carna,No.11CBS-0883C),Kinase substrate22 (GL, No.P190116-SL112393), DMSO (Sigma, No.SHBG3288V), 384well white plate (PerkinElmer, No.810712), Staurosporine (selleckchem, No.S142105)
[0403] 2: Experimental methods:
[0404] 2.1 Compound preparation
[0405] The compounds were received by the curator and dissolved in 100% DMSO to prepare a 10 mM stock solution and stored frozen at -20 °C.
[0406] 2.2 Kinase reaction process
[0407] (1) Prepare 1× Kinase buffer.
[0408] (2) Preparation of compound concentration gradient: The test compound was tested at a concentration of 1000 nM. It was diluted to a 100% DMSO solution with a 100-fold final concentration in the 384source plate. The compound was diluted 3-fold with Precision, with 10 concentrations. 250 nL of the compound with a 100-fold final concentration was transferred to the destination plate OptiPlate-384F using a dispenser Echo 550.
[0409] (3) Use 1× Kinase buffer to prepare a kinase solution with a final concentration of 2.5 times.
[0410] (4) Add 10 μL of kinase solution at 2.5 times the final concentration to the compound wells and positive control wells respectively; add 10 μL of 1× Kinase buffer to the negative control wells.
[0411] (5) Centrifuge at 1000 rpm for 30 seconds, shake the reaction plate to mix, and incubate at room temperature for 10 minutes.
[0412] (6) Use 1× Kinase buffer to prepare a mixed solution of ATP and Kinase substrate 22 at 5 / 3 times the final concentration.
[0413] (7) Add 15 μL of a mixed solution of ATP and substrate at 5 / 3 times the final concentration to start the reaction.
[0414] (8) Centrifuge the 384-well plate at 1000 rpm for 30 seconds, shake to mix, and incubate at room temperature for the corresponding time.
[0415] (9) Add 30 μL of stop detection solution to stop the kinase reaction, centrifuge at 1000 rpm for 30 seconds, and shake to mix.
[0416] (10) Read the conversion rate using Caliper EZ Reader.
[0417] 2.3 Data Analysis
[0418] Calculation formula
[0419] Where: Conversion%_sample is the conversion rate reading of the sample; Conversion%_min: the mean of the negative control wells, representing the conversion rate reading of the wells without enzyme activity; Conversion%_max: the mean of the positive control well ratio, representing the conversion rate reading of the wells without compound inhibition.
[0420] Fitting dose-effect curve:
[0421] The log value of the concentration was used as the X-axis and the percentage inhibition rate was used as the Y-axis. The log (inhibitor) vs. response–Variable slope of the analysis software GraphPad Prism5 was used to fit the dose-effect curve to obtain the IC50 value of each compound on the enzyme activity. The calculation formula is:
[0422] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope))
[0423] The test results are shown in Table 4:
[0424] Table 4 Inhibitory activity of compounds against wild-type and mutant ALK, TRK, and ROS1 kinases (IC 50 )
[0425]
[0426]
[0427] Experimental Example 2 Inhibitory Effect of Compounds on Cell Activity
[0428] 1: Cell lines
[0429] Cell lines Cell Type Number of cells / well Culture medium Ba / F3EML4-ALK-WT Suspension 3000 RPMI-1640 + 10% FBS Ba / F3EML4-ALK-L1196M Suspension 3000 RPMI-1640 + 10% FBS Ba / F3LMNA-NTRK1-G595R Suspension 3000 RPMI-1640 + 10% FBS
[0430] The cells were cultured at 37°C, 5% CO2, and 95% humidity.
[0431] 2: Reagents and consumables
[0432] Fetal bovine serum FBS (GBICO, Cat#10099-141)
[0433] CellTiter- Luminescent Cell Viability Assay(Promega,Cat#G7573)
[0434] 96-well clear flat bottom black wall plate ( Cat#165305)
[0435] RPMI-1640 (Hyclone, Cat#SH30809.01)
[0436] 3: Cell culture and inoculation:
[0437] (1) Harvest cells in the logarithmic growth phase and count the cells using a platelet counter. Detect cell viability using the trypan blue exclusion method to ensure that the cell viability is above 90%;
[0438] (2) Adjust cell concentration; add 90 μL of cell suspension to each 96-well plate;
[0439] (3) The cells in the 96-well plate were cultured overnight at 37°C, 5% CO2, and 95% humidity.
[0440] 4: Drug dilution and dosing:
[0441] (1) Prepare a 10-fold drug solution with a maximum concentration of 10 μM, 9 concentrations, and 3.16-fold dilutions (see Appendix 1). Add 10 μL of the drug solution to each well of a 96-well plate seeded with cells. Set up three replicate wells for each drug concentration. The final concentration of the compound is 1 μM, 9 concentrations, and 3.16-fold dilutions. The final DMSO concentration is 0.1%;
[0442] (2) The cells in the 96-well plate to which the drug had been added were cultured for 72 hours at 37°C, 5% CO2, and 95% humidity, and then CTG analysis was performed.
[0443] 5: End point plate reading:
[0444] (1) Thaw CTG reagent and equilibrate the cell plate to room temperature for 30 minutes;
[0445] (2) Add an equal volume of CTG solution to each well;
[0446] (3) Shake on an orbital shaker for 5 minutes to lyse the cells;
[0447] (4) Place the cell plate at room temperature for 20 minutes to stabilize the cold light signal;
[0448] (5) Read the cold light value.
[0449] 6: Data Processing
[0450] The data were analyzed using GraphPad Prism 7.0 software, and the dose-effect curve was fitted using nonlinear S-curve regression to obtain the IC50 value.
[0451] Cell survival rate (%) = (Lum 待测药 -Lum 培养液对照 ) / (Lum 细胞对照 -Lum 培养液对照 )×100%.
[0452] The test results are shown in Table 5:
[0453] Table 5 Inhibitory activity IC of compounds on Ba / F3ALK, TRK, and ROS1 cells 50 (nm)
[0454]
[0455] Test Example 3: Stability test of liver microsomes of test compounds
[0456] 1: Materials and methods
[0457] Buffer:
[0458] (1) 100 mM potassium phosphate buffer, pH 7.4; (2) 10 mM MgCl2.
[0459] Preparation of compound solution:
[0460] (1) Preparation of 100 μM working solution: Take 5 μL of the stock solution (10 mM) of the test group or the control group and dilute it with 495 μL of methanol to obtain a compound concentration of 100 μM (99% MeOH).
[0461] (2) Preparation of 10 μM working solution: Take 50 μL of 100 μM working solution and dilute it with 450 μL of 100 mM potassium phosphate buffer. The resulting compound concentration is 10 μM (9.9% MeOH).
[0462] Components of the NADPH (prototype coenzyme II) regeneration system (the final concentration of isocitrate dehydrogenase in the culture medium is 1.0 unit / mL):
[0463] β-Nicotinamide adenine dinucleotide phosphate, supplier: Chem-impex international, catalog number: N00616. Preparation of liver microsome solution (final concentration 0.5 mg protein / mL), liver microsome types are shown in Table 6:
[0464] Table 6
[0465]
[0466] Stop Solution:
[0467] An ice-cold solution in acetonitrile containing 100 ng / mL tolbutamide and 100 ng / mL labetalol as internal standards.
[0468] Steps:
[0469] (1) Except for the blank matrix well, 10 μL of the working solution of the test or control drug was added to each well (T0, T5, T10, T20, T30, T60 and NCF60).
[0470] (2) 80 μL / well of the microsome solution was dispensed onto each plate using Apricot, and the mixture of the microsome solution and the compound was incubated at 37°C for about 10 minutes.
[0471] (3) Add 10 μL of 100 mM potassium phosphate buffer / well to NCF60, incubate at 37°C, and start timer 1. The time is shown in Table 7.
[0472] Table 7
[0473]
[0474] (4) After preheating, 10 μL / well of NADPH regeneration system was dispensed onto each plate using Apricot to start the reaction.
[0475] Table 8 Final concentration of each component in the incubation medium
[0476]
[0477] (5) Incubate at 37°C and start timer 2. The data are shown in Table 9.
[0478] Table 9
[0479]
[0480] (6) Add 4°C precooled stop solution (containing internal standards 100 ng / mL tolbutamide and 100 ng / mL isothiocyanate) to each well to terminate the reaction.
[0481] (7) The sample plate is then shaken on a shaker for about 10 minutes.
[0482] (8) Centrifuge the sample at 4000 rpm for 20 min at 4°C.
[0483] (9) Take another 96-well plate and add 300 μL of HPLC-grade water to each well. Take 100 μL of the supernatant obtained by centrifugation and add it to the corresponding well. Mix the two wells and use them for LC / MS / MS detection.
[0484] Data Analysis:
[0485] Calculation of t 1 / 2 and Clint(mic) values based on first-order elimination kinetics
[0486] The first-order elimination kinetic equation is:
[0487]
[0488]
[0489]
[0490]
[0491]
[0492] The results of liver microsome stability test of some compounds are shown in Table 10:
[0493] Table 10
[0494]
[0495] Experimental Example 4: PK test of the test compound in rats
[0496] SD rats, male (purchased from Shanghai Xipuer-Bikai Experimental Animal Co., Ltd.). Each test compound was administered orally (10 mg / kg, 3 rats per group) and intravenously (1 mg / kg, 3 rats per group) to SD rats for pharmacokinetic study. The test compound was prepared on the day of administration, and the test compound was dissolved in 5% DMSO + 10% solutol + 85% saline, and the dosing solution was prepared after vortexing for 2 minutes and ultrasonication for 5 minutes. The animals were fasted for 10-14 hours before oral administration, and the feeding was resumed 4 hours after administration. After oral and intravenous administration of SD rats, pharmacokinetic samples were collected through the jugular vein. The collection time points were: before administration, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h and 24h after administration. Three whole blood samples were collected at each time point, with a collection volume of about 0.2mL, and anticoagulated with sodium heparin. After blood samples were collected, they were immediately placed on ice and centrifuged to separate plasma within 1 hour (centrifugation conditions: 6800 rpm, 6 minutes, 2-8°C). The collected plasma was stored in a -80°C refrigerator before analysis.
[0497] The pharmacokinetic test results of some compounds of the present invention are shown in Table 11 below:
[0498] Table 11 Pharmacokinetic test results of some compounds of the present invention
[0499] Example T1 / 2(iv)h Tmax(po)h Cmax(po)ng / ml AUC(po)ng / ml*h Cl(iv)ml / hr / kg F(po)% Example 1 4.32 4.00 16004 139106 66.07 93.27 Example 6 2.58 4.00 5256 47980 300.20 147.23 Example 10 2.62 4.00 5087 42423 322.41 130.17 Embodiment 11 5.35 4.00 18978 138207 60.74 92.66 Example 12 3.79 4.00 15303 139776 70.11 93.71 TPX-0005 8.17 3.33 1574 8319 1136.20 102.57
[0500] It can be seen from the above drugability research data that the compound of the present invention has a significant inhibitory effect on the activity of protein kinase inhibitors. Compared with TPX-0005 in clinical phase II, it has obvious advantages in pharmacokinetic aspects and can be used as a protein kinase inhibitor. It has broad application prospects in the treatment of malignant tumor diseases or inflammatory diseases.
Claims
1. A compound, characterized in that Having the structure represented by formula (IV) or its tautomer, mesomer, racemate, enantiomer, diastereomer or mixture form or salt thereof: ; (IV) Wherein: n is selected from 0; R2 is selected from halogen; R4 is selected from halogen; R9, R 10 , R 11 , R 14 are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, substituted or unsubstituted C1~6 alkyl or heteroalkyl, substituted or unsubstituted C3~6 cycloalkyl or heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxyl, cyano, amino; R5, R6 and the carbon atoms to which they are connected constitute a substituted or unsubstituted C3~6 cycloalkyl group; the substituents are independently selected from halogen, hydroxyl, cyano and amino.
2. The compound according to claim 1, characterized in that R9 is selected from H, halogen, and C1-3 alkyl.
3. The compound according to claim 1, characterized in that: R 10 , R 11 , R 14 Selected from H, halogen, substituted or unsubstituted C1~6 alkyl or heteroalkyl.
4. The compound according to claim 1, characterized in that: R 10 , R 11 , R 14 Selected from H.
5. The compound according to claim 1, characterized in that: R4 is selected from F, Cl, Br.
6. The compound according to claim 1, characterized in that R9 is selected from H.
7. The compound according to claim 1, characterized in that R5, R6 and the carbon atom to which they are connected constitute a substituted or unsubstituted cyclopropyl group.
8. The compound according to claim 1, characterized in that for .
9. A compound, characterized in that: Having the structure represented by formula (V) or its tautomer, mesomer, racemate, enantiomer, diastereomer or mixture form or salt: ; (V) Wherein: n is selected from 0, 1 or 2; R2 is selected from halogen; R4 is selected from halogen; R9, R 10 , R 11 , R 14 are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, substituted or unsubstituted C1~6 alkyl or heteroalkyl, substituted or unsubstituted C3~6 cycloalkyl or heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxyl, cyano, amino; R 23 Selected from hydrogen, halogen, unsubstituted C1~6 alkyl or heteroalkyl, unsubstituted C3~6 cycloalkyl or heterocycloalkyl; R5, R8, the carbon atoms to which they are connected, and the saturated chain segments of the macrocyclic molecules between the two carbon atoms together constitute a substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, wherein the heterocycloalkyl contains one or more O or NR 25 , the substituents are independently selected from halogen, hydroxyl, cyano, and amino; R 25 is selected from hydrogen, substituted or unsubstituted C1~6 alkyl, substituted or unsubstituted C3~6 cycloalkyl, wherein the substituent is selected from halogen, hydroxyl, cyano, amino; R3 is selected from hydrogen; Y is selected from O.
10. The compound according to claim 9, characterized in that: R4 is selected from halogen; R9 is selected from H, C1~3 alkyl or heteroalkyl; R 23 Selected from H, halogen, C1~3 alkyl; R5, R8, the carbon atoms to which they are connected, and the saturated chain segments of the macrocyclic molecules between the two carbon atoms together constitute a substituted or unsubstituted C3-6 cycloalkyl or heterocycloalkyl, wherein the heterocycloalkyl contains one or more O or NR 25 , the substituents are independently selected from F, Cl, Br, hydroxyl, cyano, and amino; R 25 is selected from hydrogen, substituted or unsubstituted C1~3 alkyl, wherein the substituents are independently selected from hydroxyl or amino.
11. The compound according to claim 9, characterized in that: R 10 , R 11 , R 14 Selected from H, halogen, substituted or unsubstituted C1~6 alkyl or heteroalkyl.
12. The compound according to claim 11, characterized in that: R 10 , R 11 , R 14 Selected from H.
13. The compound according to claim 9, characterized in that: R 10 , R 11 , R 14 Selected from H.
14. The compound according to any one of claims 9 to 10, characterized in that: R4 is selected from F, Cl, Br.
15. The compound according to any one of claims 9 to 10, characterized in that: R5, R8 and the carbon atoms to which they are respectively connected and the saturated chain segment of the macrocyclic molecule between the two carbon atoms together constitute a substituted or unsubstituted C3~6 cycloalkyl group, and the substituents are independently selected from F, Cl, Br, hydroxyl, cyano, and amino; Y is O.
16. The compound according to claim 15, characterized in that: R5, R8 and the carbon atoms to which they are respectively connected and the saturated chain segment of the macrocyclic molecule between the two carbon atoms together constitute a substituted or unsubstituted cyclobutyl, cyclopentyl or cyclohexyl group.
17. The compound according to claim 15, characterized in that: R5, R8 and the carbon atoms to which they are respectively connected and the saturated chain segment of the macrocyclic molecule between the two carbon atoms together constitute a substituted or unsubstituted cyclopentyl or cyclohexyl group.
18. The compound according to claim 9, characterized in that: for or .
19. The compound according to claim 18, characterized in that for or .
20. The compound according to claim 9, characterized in that: n is selected from 0 or 1.
21. The compound according to claim 9, characterized in that: R4 is selected from halogen.
22. A pharmaceutical composition, characterized in that The active ingredient of the pharmaceutical composition is selected from the compound described in any one of claims 1 to 21 or one or a combination of two or more of its tautomers, mesomers, racemates, enantiomers, diastereomers or salts thereof.
23. Use of the compound according to any one of claims 1 to 21 or its tautomer, mesomer, racemate, enantiomer, diastereomer or salt thereof in the preparation of a protein kinase inhibitor, characterized in that: The kinase inhibitor is selected from one or more of ALK inhibitors, ROS1 inhibitors, and TRK inhibitors.
24. Use of the compound according to any one of claims 1 to 21 or its tautomer, mesomer, racemate, enantiomer, diastereomer or salt thereof in the preparation of a drug for treating diseases caused by overexpression of ALK, ROS1 or TRK kinases.
